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2 Introduction 
_______________________________________________________________ 
Worldwide, 3.3 billion people are at risk for malaria in 97 countries and 
territories and more than one third of those are at high risk of infection (>1 in 
100 chance to get malaria in a year) [1]. According to the  latest estimates,198 
million  cases of malaria occurred globally in 2013 (uncertainty range 124–283 
millions), and the infection led to 584 000 deaths (uncertainty range 367 000-
755 000) [1].  Malaria is due to human infection of Plasmodium sp. protozoan; 
nowadays species infective to humans consist in P. falciparum, P vivax, 
P.malariae, P. knowlesii and the newly proposed species of P. ovale curtisi 
(former classic type) and P. ovale wallikeri (former variant type) [2-4]. Most 
cases of malaria occur in Africa (80%) where the majority of infections are 
caused by P. falciparum, the most virulent of all the human malaria parasites. 
Moreover, of the global total of malaria deaths in 2013, 90% were estimated to 
occur in the Sub-Saharan Africa and 78% of the total deaths occurred in 
children under 5 years of age in the region [1]. Thereby it is not surprising that 
malaria nowadays is considered as the fifth global greatest cause of death in 
under 5 years old [5, 6].  
Whilst malaria incidence and mortality has decreased in the recent years due to 
multidisciplinary and globally coordinated interventions [1], the spread of drug-
resistant parasites is still one of the most important points at issue in malaria 
control strategies [7]. Former commonly used antimalarials, such as most 
aminoquinolines, have become increasingly ineffective, leading to an urgent 
need for new treatment options [8]. Children and pregnant women are 
inherently vulnerable to malaria infection and the need of treatment is of high 
importance in the fight against the disease in this populations. Presently, 
artemisinin-based combination therapy (ACT) is recommended by the WHO 
Global Malaria Program as the first-line treatment for malaria [8, 9], and there is 
a need for new regimens that are affordable, convenient, effective and safe. Yet 
appropriate drug formulation is an essential factor for the success of the 
strategy of artemisinin-based combination therapy in children and oral 
paediatric formulations are urgently needed.  
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2.1 Antimalarial Combination Therapy  
Antimalarial combination therapy is defined as “the simultaneous use of two or 
more blood schizontocidal drugs with independent modes of action and thus 
unrelated biochemical targets in the parasite” [8]. The principal assumption of 
combination therapy is that “the probability of resistance developing 
simultaneously to two chemotherapeutic agents with independent mechanisms 
of action is extremely low”, of the order of once in 1012 treatments [10]. This 
frequency is the product of the probabilities of the independent acquisition of a 
resistant mutation to each drug multiplied by the number of parasites in a typical 
infection, therefore reducing -at least in theory- the likelihood of resistant 
parasites being selected and transmitted. 
Antimalarial combination therapies can be distinguished in two main groups: the 
artemisinin combination therapies (ACT) and the non-artemisinin based 
combinations (non-ACT). Currently available non-artemisinin based 
combination regimens include sulfadoxine-pyrimethamine, chloroquine plus 
sulfadoxine-pyrimethamine, quinine plus sulfadoxine-pyrimethamine, 
amodiaquine plus sulfadoxine-pyrimethamine, mefloquine plus sulfadoxine-
pyrimethamine, quinine plus tetracycline-doxycicline, quinine plus clindamycin 
and atovaquone-proguanil. Chlorproguanil-dapsone has been withdrawn 
following increased evidence of haematological toxicity [11]. Quinine-
sulfadoxine-pyrimethamine, amodiaquine-sulfadoxine-pyrimethamine and 
mefloquine plus sulfadoxine-pyrimethamine are regarded to have acceptable 
levels of efficacy while desirable efficacy has been shown for 
quinine-tetracycline, quinine-clindamycin, and atovaquone-proguanil [12]. 
However, effectiveness is sub-optimal for all treatments necessitating repeated 
doses over more than 3 days. The prevailing high levels of resistance to 
chloroquine and amodiaquine have compromised the efficacy of these two 
drugs even in combinations. There is no evidence that the combination of 
chloroquine plus sulfadoxine-pyrimethamine gives any additional gain over 
sulfadoxine-pyrimethamine alone, thus the combination is not recommended 
anymore; sulfadoxine-pyrimethamine plus amodiaquine has been observed to 
be more effective than either drug alone though the efficacy of this combination 
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is actually inferior to ACT so it is not recommended anymore for the treatment 
of  P. falciparum malaria  [13].  
The effect of combination therapy is thus improved by including an artemisinin 
derivative. Parasite density is diminished more rapidly by artemisinin-based 
antimalarials than by any other antimalarial drug [14]. The period of parasite 
exposure to sub-therapeutic blood levels is minimized when artemisinin 
derivatives are used alone due to their short half-life. When combined with 
drugs with longer half-life, the rapid parasite clearance time of artemisinin 
derivatives and their short half-life imply that exposure to the partner drug after 
the artemisinin component is eliminated attains many fewer parasites. 
Moreover, parasite exposure to the companion drug occurs when blood levels 
are close to the maximum [10]. An additional benefit for treated patients with 
artemisinin combinations is the 90% reduction of gametocyte density [15]. 
Taken together, all these characteristics minimize the probability of a resistant 
mutant surviving antimalarial therapy and could thus reduce overall malaria 
transmission rates. 
There are two additional reasons for the concept of combining antimalarials:  
to increase efficacy and to shorten duration of treatment. The enhancement of 
therapeutic efficacy has been a major issue since drug resistant strains of P. 
falciparum have rendered many former antimalarial monotherapeutic regimens 
ineffective. Simultaneous administration of two independent drugs has proven 
to overcome this decreased efficacy of monotherapy by acting on different 
biochemical targets. Finally, the potential of drug combinations to shorten 
duration of treatment has been shown in a number of clinical trials. A further 
advantage thereby is that patients’ compliance is improved with shorter 
treatment courses, which is again related to effectiveness and development of 
drug resistance.  
Artemisinins should not be used as a single agent, to prevent emergence of 
drug resistance and to avoid the need for prolonged therapy [9]. Artemisinin-
based combination therapy combines the highly effective short-acting 
artemisinins with a longer-acting partner to protect against artemisinin 
resistance and to facilitate dosing convenience. ACTs are typically administered 
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for three days and have been recently developed mainly in fixed-dose tablets. 
Besides pyronaridine-artesunate, five ACTs have been recommended by the 
WHO for the treatment of uncomplicated malaria: artemether-lumefantrine, 
artesunate-amodiaquine, artesunate-mefloquine, artesunate-sulfadoxine-
pyrimethamine, and dihydroartemisinin-piperaquine [13]. Artemether-
lumefantrine appears to be the most widely adopted ACT in Africa, followed by 
artesunate-amodiaquine [16]. Though the different artemisinin derivatives show 
some minor differences regarding oral absorption and bioavailability, these 
differences are not clinically significant within currently available formulations. 
The efficacy of the ACT is therefore mostly determined by the proprieties of the 
partner medicine and these proprieties are considered for the choice of 
combination. As resistance to the artemisinins’ partner medicines may 
compromises the efficacy of the ACT [8], the proprieties of the partner drug of 
the artemisinin derivative in ACTs such as resistance and tolerability may affect 
choice. Artesunate- mefloquine, artemether-lumefantrine or dihydroartemisinin-
piperaquine have the highest cure rates in many countries [17-21]. The use of 
artesunate-mefloquine in African children was subsequently restricted due to 
excessive vomiting associated with the recommended dose (25 mg/kg) of the 
partner drug. However, further evaluation showed that the tolerability to 
artesunate-mefloquine in children weighing between 10-20 kg was as good as 
with artemether-lumefantrine [18]. In some African regions, artesunate-
amodiaquine or sulfadoxine-pyrimethamine are still considered effective options 
due to the low levels of resistance to amodiaquine and sulfadoxine-
pyrimethamine. However, these two drugs remain widely available as 
monotherapy and despite the deployment of corresponding combination with 
artemisinin derivatives, resistance to amodiaquine and sulfadoxine-
pyrimethamine will probably continue to worsen due to continue selection 
pressure. 
A key to many limitations associated with artemisinin-based combination 
therapy seems to be the pharmacokinetic mismatch of the partner drugs [22]. A 
pharmacokinetic mismatch can also be a major factor contributing to resistance 
of the long-acting partner drug, which in the later stages of its presence in the 
blood stream is not protected by the short-acting artemisinins. This is not a 
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problem as long as both drugs are fully efficacious on their own and as long as 
the drug levels of both drugs remain above the minimum inhibitory 
concentrations until all asexual parasites have been cleared. However, with a 
reasonable duration of drug administration, short half-life drugs will not be able 
to cover the minimum duration of drug exposure. At the same time, long half-life 
drugs will inevitably result in drug levels of the partner drugs below the minimum 
inhibitory concentrations and without protection from the artemisinin compound. 
This particularly applies to the use of artemisinin-based combination therapy in 
high transmission areas [23], as widespread use of such combinations would 
result in exposure of parasites to low doses of those drugs in case of re-
infection after treatment. 
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2.2 Drug Formulation of Combination Treatment 
Regimen 
Besides effectiveness, safety, tolerability and accessibility of antimalarials, 
adherence to treatment has been characterized as a major determinant for 
successful treatment of malaria, especially when dealing with rural populations 
in developing countries [13]. In general, compliance with sequential combination 
regimen of antimalarial drugs tends to be problematic with patients unwilling to 
take antimalarials after clinical improvement. This is a particular danger for 
artemisinin-containing combinations, as they resolve clinical symptoms such as 
fever quicker than all other antimalarials. This relief of symptoms might easily 
be interpreted as cure, making patients reluctant to continue treatments as 
prescribed, which may quickly lead to recrudescent parasitaemia. Therefore, a 
potential problem of treating patients with more than one antimalarial drug is the 
fact that many currently available combination therapies are not co-formulated, 
greatly increasing complexity of treatment and the chances of misuse. In order 
to reduce the potential selective pressure of drugs used as monotherapy and to 
improve adherence to treatment, fixed-dose combination formulations are 
strongly advised and preferable over blistered loose tablets or even co-
packaged combinations [9, 13]. Fixed-dose combinations are now available for 
the following recommended artemisinin-based combinations: artemether-
lumefantrine, artesunate-amodiaquine, artesunate-mefloquine and 
dihydroartemisinin–piperaquine. However, the widely used co-formulation 
artemether–lumefantrine remains a relatively complex regimen (with a children 
dose of two tablets twice daily for 3 days) and compliance, and therefore 
programmatic effectiveness, is not optimal [24]. Yet artemether-lumefantrine 
dispersible tablets, artesunate-amodiaquine water-soluble tablets and 
dihydroartemisinin-piperaquine liquid formulation are the only drugs available 
for oral liquid administration for children included on the list of prequalified 
medicinal products of the WHO [25]. Fixed-dose combination formulations of 
artemisinin-based combinations are technically difficult, and therefore it is 
essential that any new combination is shown to have adequate ingredient 
compatibility, optimal stability, and similar oral absorption rate and bioavailability 
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to the loose or co-blistered tablets. Certainly, there is a need of new ACT 
formulations specifically developed for use in pediatric populations. 
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2.3 The Combination of Artesunate and Pyronaridine 
2.3.1 Artesunate 
The artemisinins are derived from 
the leaves of the Chinese sweet 
wormwood plant, Artemisia annua. 
They have been used in China by 
herbal medicine practitioners for 
many centuries as a  treatment of 
fever and malaria [26] and came to 
attention outside this country in the 
1970s and 1980s [27].  
                                         
Artesunate  [Public domain]  
Source: http://commons/File%3AArtesunate.svg
Artemisinin containing endoperoxide, originally known as Qinghaosu (青蒿素) 
was firstly isolated in 1972 by Chinese scientists [28]. Since then and due to the 
emergence of P. falciparum resistance to commonly used antimalarials, 
artemisinin derivatives have become widely used. Nowadays they are the 
cornerstone of nearly all new combination therapies. Even in multidrug resistant 
P. falciparum malaria, artemisinin derivatives show remarkably high activity 
such as rapid resolution of fever and parasitaemia [29, 30]  . 
The mechanism of action of artemisinins seems to involve iron-binding and 
breaking down peroxide bridges leading to the generation of free radicals that 
damage parasite protein, being the SERCA-type PfATPase6, a sarco-
/endoplasmatic reticulum Ca++-ATPase the proposed specific target of the 
compound [31]. They act rapidly, killing blood stages of all Plasmodium species 
and reducing the parasite biomass [14]. Artemisinins have the fastest parasite 
clearance times of any antimalarial [32] and are most effective against late ring 
to early trophozoite stages. Artemisinins are active against gametocytes and 
their use has been associated with reduced malaria transmission [33]. 
Currently, artemisinin derivatives used in clinical practice include artemether, 
dihydroartemisinin and artesunate [13].  
Artesunate is a water-soluble hemisuccinate ester of the original sesquiterpene 
lactone artemisinin. It can be administered orally, rectal, intravenously or 
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intramuscularly as artesunic acid. As for all artemisinin derivatives, 
dihydroartemisinin (DHA) appears to be the principal active metabolite of 
artesunate in vivo [34]. Biotransformation of artesunate to dihydroartemisinin is 
very rapid, yet the degree at which artesunate is transformed varies 
considerably [35, 36].  Hydroxylation of artesunate to dihydroartemisinin is pH 
dependent and seems to occur already in the gastrointestinal tract [37] , which 
means that the drug is partly absorbed in form of its metabolite. In the blood, 
hydrolysis of artesunate is catalysed by esterases [38]. Dihydroartemisinin 
binds moderately to human plasma proteins, predominantly to albumin [39]. It is 
quickly eliminated from plasma with an elimination half-life time of 
approximately one hour. Dihydroartemisinin undergoes glucuronidation in liver 
microsomes, and is mainly excreted via the urine as alpha-dihydroartemisinin-ß-
glucuronide [34] .  
Intravenous artesunate alone is used as the initial treatment of severe malaria. 
It is superior to quinine for treatment of severe malaria with respect to clearing 
parasitaemia and reducing mortality [40]. Given the short half-life of 
artemisinins, intravenous therapy must be followed by a longer acting agent 
once the patient is able to tolerate oral medication. Treatment for less than five 
days of artesunate alone by any route (parenteral, rectal or oral) results in 
recurrent parasitaemia several weeks after therapy due to the very short 
duration of action, rather than to artemisinin resistance [41]. 
Artemisinins are generally well tolerated [42, 43]. Type 1 hypersensitivity to the 
artemisinin compounds has been reported (incidence 1:3000) [44]. A large-
scale study on the adverse effects of orally-administered artemisinins 
demonstrated transient neurological abnormalities, including nystagmus and 
disturbances in balance; these effects resolved without lasting sequelae [43]. 
Transient neutropenia has been observed rarely in individuals receiving oral 
artesunate at doses higher than that typically prescribed [45]. Furthermore, 
attention has been recently drawn to the possible delayed hemolysis after 
artesunate in severe malaria [46-49]. While the pathophysiology of this 
phenomenon has not yet been fully elucidated, the necessity of standardized 
follow-up after treating with artesunate those patients suffering of severe 
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malaria has been therefore underlined [50]. Regarding resistance to 
artemisinins derivatives, reduced susceptibility as evidenced by delayed 
parasite clearance time, has been demonstrated in western Cambodia [51] and 
the bordering regions with Thailand [52]. The underlying mechanism and its 
long term clinical implications are not known.  
 
2.3.1 Pyronaridine 
Pyronaridine, 2-methoxy-7-chloro-10 
[3,5-bis-(pyrrolidinyl-1- 
methyl4-hydroxyphenyl] 
aminobenzyl-(b)-1,5-naphthyridine, 
is a highly active blood 
schizonticidal Mannich-base 
antimalarial drug. It was firstly 
developed in China in 1970 [53]. 
 
Pyronaridine  [Public domain]  
Source: http://commons/File%3APyronaridine.svg 
 
Pyronaridine was one of the first synthetically developed antimalarial drugs after 
chloroquine [54]. Structurally, pyronaridine is related to the aminoacridine drug 
quinacrine. The drug is highly effective against erythrocytic stages of P. 
falciparum and P. vivax [55, 56] and had been used against these Plasmodium 
species for over thirty years as a monotherapy in China [57]. 
Early studies showed that pyronaridine seems to affect the food vacuole of the 
parasite [58, 59], followed by the fast formation of an structure of multilamellar 
whorls in the trophozoites’ pellicular complexes [59]. In infected primates a 
single membrane surrounding undigested endocytic vesicles of parasites 
exposed to pyronaridine was observed. The most specific and earliest effect of 
therapy was shown to interfere with the parasite food vacuole of schizonts and 
late trophozoites [60]. The anti-plasmodial activity of the compound seems to 
involve interference with the glutathione-dependent detoxification of haem [61, 
62] and targeting of β-haematin formation [63]. Pyronaridine has been shown to 
inhibit β-haematin production with a 50%-inhibitory concentration similar to that 
of chloroquine. Moreover, forming complexes with β-haematin enhance 
haematin-induced human blood cell lysis by approximately 1/100 of the 
Introduction 
 
14 
concentration needed with chloroquine [61]. Furthermore,  P. falciparum DNA 
topoisomerase II seemed to be inhibited by pyronaridine and anilinoacridine 
analogs [63]. However, it appeared that the compound does not elicit formation 
of a protein-DNA complex in situ but the formation of a drug-haematin complex 
[61] . 
Advantages of pyronaridine include its structural differences to other 
antimalarial drugs, long shelf-life and once-daily dosing [57]. In animal models 
of malaria infection, pyronaridine showed synergistic activity with artesunate 
against strains resistant to either component [64]. Furthermore, it is efficacious 
in combatting chloroquine-resistant strains of falciparum malaria both in vitro 
and in vivo in human patients [65, 66]. However, there have been concerns 
about the emergence of resistance if used as monotherapy [64, 67].  
Pyronaridine monotherapy seems to have no relevant effect on gametocyte 
carriage of P. falciparum in children and adults. However, in patients who had 
chloroquine-resistant infection, chloroquine has been associated with a higher 
relative risk for gametocytaemia after treatment compared to pyronaridine [68]. 
It has been therefore suggested a relative small benefit of pyronaridine for 
gametocyte carriage compared to chloroquine in areas where chloroquine-
resistant P. falciparum is present. Pyronaridine has been also investigated in P. 
ovale spp (n = 8) and P. malariae infection (n =14) [69]. Mean parasite and fever 
clearance times were respectively 50 h and 33 h, while no patient had fever 
after Day 4. All patients were considered clinically and parasitological cured at 
Day 14. 
The tolerability and safety profile of pyronaridine as monotherapy has shown 
the drug to be generally well tolerated. The common adverse events described 
after oral pyronaridine therapy have been usually similar to the symptoms of 
malaria, i.e. dizziness, nausea, vomiting and abdominal discomfort [57] 
Transient ECG changes as well as palpitations and allergic skin reaction have 
also been noted at higher doses of pyronaridine [53]. Pruritus, an adverse 
reaction seen related to many antimalarials in patients of African origin, has 
been described in a cohort in Cameroon patients treated with pyronaridine, 
though 2.5 times lower than in chloroquine-treated patients [70]. In this study, 
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seven patients treated with pyronaridine showed increased serum 
transaminases transiently after treatment as well as four patients treated with 
chloroquine. Moreover, in five patients receiving pyronaridine total bilirubin was 
slightly elevated. In Thailand, seven patients receiving 1,200 mg-1,800 mg 
pyronaridine had increased transaminases at Day 7; all cases resolved within 
five weeks after treatment start [71]. Finally, there is some evidence of 
successfully cured malaria in pregnancy, treated with pyronaridine at their mid- 
and late-trimester with no known adverse effects [72].  
 
2.3.2 Combination Therapy in Malaria 
Pyronaridine-artesunate (3:1 ratio, fixed dose once daily for three days) has 
been developed as an artemisinin-based combination for the treatment of 
uncomplicated P. vivax and P. falciparum malaria [73]. In a Phase II open-label 
study in 60 children with falciparum malaria in Gabon, pyronaridine-artesunate 
(tablets or granules) given in ratios of 6:2 mg/kg, 9:3 mg/kg, or 12:4 mg/kg once 
daily for 3 days showed good tolerability and safety profile, with a PCR-
corrected cure rate of 100% on Day 28 [73]. Furthermore, rates of adequate 
clinical and parasitological response (ACPR) on Day 28 for pyronaridine-
artesunate tablet formulation therapy (corrected for re-infection with polymerase 
chain reaction genotyping) were respectively 99.5% (780/784) and 99.2% 
(743/749) in two clinical trials, both conducted in adults and children with P. 
falciparum malaria in Africa and Asia, [74, 75]. Antimalarial therapy with 
pyronaridine-artesunate was non-inferior to that with artemether-lumefantrine 
and artesunate plus mefloquine, respectively. Moreover, the profile of adverse 
events of pyronaridine-artesunate in these clinical trials was considered to be 
adequate, though some patients had transient increased liver transaminases. 
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2.4 Study Objectives 
Artemisinin-based combination therapy is now the recommended treatment for 
uncomplicated P. falciparum malaria. Appropriate drug formulation is an 
essential factor for the success of the strategy of artemisinin-based combination 
therapy and oral paediatric formulations are urgently needed. 
The primary objective of this clinical study was to demonstrate the efficacy of a 
fixed combination of pyronaridine-artesunate granule formulation (60:20 mg) by 
showing a PCR-corrected adequate clinical and parasitological cure rate of 
more than 90% in African children of 5-20 kg body weight and 1-12 years old. 
The secondary objective of this study was to compare the efficacy (non-
inferiority) and safety of pyronaridine-artesunate granule formulation compared 
to Coartem® crushed tablets in a pediatric population and to assess the safety 
of pyronaridine-artesunate granule formulation. Both treatments are a three 
days regimen course and are formulated specially for the use in pediatric 
patients. Pyronaridine-artesunate granule formulation additionally addressed 
the need for an ACT regimen for young children with difficulties to swallow 
tablets, facilitating compliance and thereby increasing effectiveness of treatment 
and reducing the risk of emergence of resistance. 
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3 Methods 
_______________________________________________________________ 
The study was part of a multicenter, comparative, randomized, open-labeled, 
parallel group study on the efficacy, safety and pharmacokinetics of 
pyronaridine-artesunate conducted in a total of 534 male and female infants and 
children (between ≥ 5 kg and < 25 kg body weight) suffering from acute 
symptomatic uncomplicated P. falciparum malaria recruited from study sites 
located in Africa and Philippines [76]. Patients were randomized to either 
pyronaridine-artesunate granules (paediatric Pyramax®) or artemether- 
lumefantrine (Coartem®) crushed tablets in a 2:1 ratio. A total number of 80 
children suffering from acute symptomatic P. falciparum malaria were included 
at the “Centre de Recherches Médicales de Lambaréné” (CERMEL) situated at 
the Albert Schweitzer Hospital in Lambaréné, Gabon. 
 
Figure 1. Location of centres of recruitment in Africa and Philippines and percentage of 
total included patients recruited at each site 
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3.1 Study Site 
The study was conducted at the Albert Schweitzer Hospital in Lambaréné, 
Gabon. Lambaréné is a town of about 20.000 inhabitants and is located in a 
region of dense rainforest. The predominant Plasmodium species in Gabon is 
P. falciparum, though infection by P. ovale and P. malariae can be found. 
P. falciparum mean parasite densities are typical for areas with stable perennial 
hyperendemic malaria [77-79]. The entomological inoculation rate is around 
50 bites per person per year [79]. In vitro and in vivo high-resistance to 
chloroquine has been shown in clinical specimens in and around the area [80-
82]. A decreasing sensitivity to antifolates has been likewise reported [83, 84]. 
Susceptibility to mefloquine [77] and quinine remains high despite broad 
administration for a long time [83-85]. Regarding the activity of artemisinins 
derivatives, early in vitro studies reported high susceptibility of P.falciparum 
isolates to artesunate [83]. Moreover, consistent 50% and 90% effective 
concentrations with dihydroartemisinin have been reported against fresh 
isolates [86]. In clinical trials, a 3-day course of artesunate at a dose of 4 mg/kg 
in children with P. falciparum malaria failed to achieve sufficiently high cure 
rates (92% by Day 14 and 72% by Day 28 [41]. Although resistance to 
artemisinin derivatives has been induced in vitro, treatment failure of artesunate 
seemed to be of limited clinical relevance in the region due to high 
recrudescence rates when too short course of artesunate is used in 
monotherapy as a 5-day course of oral artesunate yielded a cure rate of 90% on 
Day 28. [41, 87].  
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3.2 Trial Population 
Infants and children with acute symptomatic uncomplicated P. falciparum 
malaria were recruited in the vicinity of Lambaréné. Patients were deemed 
eligible for the study if they met the following inclusion criteria:  
 
 Male or female patients < 12 years of age. 
 Body weight > 5 kg and < 25 kg with no clinical evidence of severe 
malnutrition (defined as a child whose weight-for-height is below 3 
standard deviations or less than 70% of the median of the NCHS/WHO 
normalised reference values).  
 Presence of acute uncomplicated P. falciparum monoinfection confirmed 
by:  
o Presence of P. falciparum with parasite density between 1,000 
and 200,000 asexual parasites/µl of blood and 
o Fever, as defined by axillary temperature above 37.5°C or 
oral/tympanic/rectal temperature above 38°C, or documented 
history of fever in the previous 24 hours 
 Written informed consent provided by parent/guardian. If the 
parent/guardian was unable to write, witnessed consent procedures were 
performed. Where possible, patient assent was sought.  
 Ability to swallow pre-specified volume of liquid in which medication was 
suspended.  
 Female patients of child-bearing potential were neither pregnant (as 
demonstrated by a negative pregnancy test) nor lactating, and willing to 
take measures to not become pregnant during the study period.  
 Ability and willingness to participate based on information given to parent 
or guardian and access to health facility. The patient was to comply with 
all scheduled follow up visits until Day 42. 
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Patients who met the following exclusion criteria were not enrolled: 
 
 Patients with signs and symptoms of severe/complicated malaria 
requiring parenteral treatment according to the World Health 
Organization Criteria 2000.  
 Mixed Plasmodium infection.  
 Severe vomiting, defined as more than three times in the 24 hours 
prior to inclusion in the study or inability to tolerate oral treatment, or 
severe diarrhoea defined as 3 or more watery stools per day.  
 Known history or evidence of clinically significant disorders such as 
cardiovascular (including arrhythmia, QTc interval greater or equal to 
450 milliseconds), respiratory (including active tuberculosis), history 
of jaundice, hepatic, renal, gastrointestinal, immunological (including 
active HIV-AIDS), neurological (including auditory), endocrine, 
infectious, malignancy, psychiatric, history of convulsions or other 
abnormality (including recent head trauma).  
 Presence of significant anaemia, as defined by Hb < 8 g/dL.  
 Presence of febrile conditions caused by diseases other than malaria.  
 Known history of hypersensitivity, allergic or adverse reactions to 
pyronaridine, lumefantrine or artesunate or other artemisinins.  
 Patients with known disturbances of electrolytes balance, e.g., 
hypokalaemia or hypomagnesaemia.  
 Use of any other antimalarial agent within 2 weeks prior to start of the 
study as evidenced by reported patient history.  
 Pregnant or breast feeding.  
 Patients taking any drug which is metabolised by the cytochrome 
enzyme CYP2D6 (flecainide, metoprol, imipramine, amitriptyline, 
clomipramine).  
 Received an investigational drug within the past 4 weeks.  
 Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen 
(HBsAg) or Hepatitis C antibody (HCV Ab).  
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 Known positive for HIV antibody.  
 Liver function tests [ASAT/ALAT levels] more than 2.5 times upper 
limit of normal range.  
 Known significant renal impairment as indicated by serum creatinine 
of more than 1.4 mg/dl.  
 Previous participation in any clinical study with pyronaridine-
artesunate.  
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3.3 Investigational Plan 
The study was designed as a comparative, randomized, open-labeled, parallel 
group study. Patients were randomized to receive either oral pyronaridine- 
artesunate granule formulation (60:20 mg sachet) once a day for 3 consecutive 
days (Day 0, 1 and 2) or artemether-lumefantrine (20:120 mg crushed tablets) 
twice a day for 3 consecutive days (Day 0, 1 and 2). For pyronaridine- 
artesunate, the actual range covered by this regimen was 7.0:2.3 mg/kg to 
13.3:4.4 mg/kg. The dose range had been shown to be well tolerated from 
phase I studies conducted in healthy volunteers and effective and well tolerated 
in phase II studies in malaria patients, including children. 
Posology was based on body weight ranges for both pyronaridine-artesunate 
combination and the comparator regimen. 
The efficacy endpoints and schedule of assessments selected followed the 
WHO guidelines for monitoring anti-malarial drug efficacy [88]. Patients were 
followed for 42 days, with the primary efficacy endpoint occurring at 28 days 
after initiation of study drug administration (Day 28). Patients were confined to 
the study facility for at least 4 days (Study Day 0, 1, 2 and 3) and remained in 
the vicinity (to rapidly address any safety issue) of the study site for a further 3 
days or when fever and parasite had been cleared for at least 24 hours (see 
definitions, page 71), whichever was the earlier. The patient returned to the 
study site for scheduled follow up visits until completion of the study on Day 42. 
In the case of adverse events were reported and unresolved at visit Day 42, 
patients were followed up for up to a further 30 days, or until resolution of the 
event whichever was the earlier. Severe adverse events were followed up to 
resolution. 
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3.4 Investigational Drugs 
Patients who met all entry criteria and presented no exclusion criteria were 
included in the study and randomized to receive either the study drug or the 
comparator drug. 
 
3.4.1 Drug Administration  
Study drug and comparator drugs were administered to patients by a qualified 
member of the study site and who was designated by the Principal Investigator. 
The medication was taken under the supervision of an investigator who 
documented drug administration time. The investigator who dispensed and 
administered the study medication did not participate in any assessment of the 
patients. The remainder of the site staff was blinded to treatment and was not 
informed of treatment allocation unless the blind needed to be broken for a 
medical emergency. Patient weight recorded during the physical examination at 
screening was used to calculate the number of tablets to be administered.Study 
drug and comparator drug were given to each patient, with up to 150 ml (full 
glass) of not carbonated liquid. All patients took the medication in an upright 
position (seated or standing) and immediately after preparation. 
If a patient vomited first dose of treatment within 30 minutes after 
administration, the full dose was replaced. The dose was not replaced if 
vomiting occurred more than 30 minutes after intake. If a patient vomited twice 
the first dose or any of the subsequent doses within 30 minutes, the study 
medication was discontinued and a rescue treatment with a standardized 
alternative antimalarial was initiated. Any new additional medication taken 
during the 42-day study period was documented in the case report form. 
Medication with antimalarial activity was not used within the 14 days period prior 
to enrolment or during the entire study period. 
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3.4.2 Study Drug: Pyronaridine-Artesunate Granules 
Pyronaridine artesunate was supplied by Shin Poong Pharm Co in aluminium 
sachets. The active ingredients of the investigational product were pyronaridine 
tetraphosphate and artesunate. Each sachet contained 60:20 mg pyronaridine 
artesunate. Depending on their body weight, patients had received 1 sachet (5-
9 kg) 2 sachets (9-17 kg) or 3 sachets (17-25 kg) per day. The dose-level range 
covered by this regimen was between 7.0:2.3 mg/kg to 13.3:4.4g/kg 
pyronaridine-artesunate, respectively.  
 
3.4.3 Artemether-Lumefantrine Crushed Tablets 
The comparator drug Coartem® was supplied by Novartis SA. The active 
ingredients of Coartem® are artemether 20 mg and lumefantrine 120 mg in a 
fixed dose combination. 
The posology was 1 crushed tablet for patients weighting 5 to <15 kg, 2 crushed  
tablets for patients weighting 15 to <25 kg twice a day for three days, the 
second dose given 8 hours after the first one and the third dose 24 hours after 
the first. The following 3 doses were given every 12 hours. 
 
 Table 1 Dosing scheme 
   
 Treatment Group 1 
60:20 mg  
Pyronaridine Artesunate 
Treatment Group 2 
20:120 mg 
Artemether Lumefantrine  
 Sachet  Oral Fixed Tablet 
   
Day 1 1 , 2 or 3 sachets depending 
on body weight 
1-2 crushed tablet depending on 
body weight 
1-2 crushed tablet 8 hours after first 
dose 
   
Day 2 1 , 2 or 3 sachets depending 
on body weight 
1-2 crushed tablets 24 hours after 
first dose 
1-2 crushed tablets every 12h 
   
Day 3  1 , 2 or 3 sachets depending 
on body weight 
1-2 crushed tablets every 12h 
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3.5 Study Design 
Study Endpoints 
The primary efficacy endpoint of the study was pyronaridine-artesunate Day 28 
PCR-corrected adequate clinical and parasitological response (ACPR) >90%.  
The main secondary efficacy endpoint was non-inferiority of pyronaridine-
artesunate to artemether-lumefantrine for Day 28 PCR-corrected ACPR [88].  
Treatment failures were classified as early treatment failure, late clinical failure, 
and late parasitological failure according to WHO criteria [88].  
 
Other secondary efficacy outcomes were:  
 Day 28 crude (non-PCR corrected) ACPR  
 Day 42 PCR-corrected and crude ACPR 
 parasite clearance time (time from first dose until clearance of 
parasitaemia, i.e. two consecutive negative readings taken between 7 
and 25 h apart) 
 fever clearance time (time from first dose to apyrexia, i.e. two 
consecutive normal readings taken between 7 and 25 h apart) 
 proportion of patients with parasite clearance or fever clearance on Day 
1, 2, and 3 
 Exploratory efficacy outcomes were:  
 gametocyte density and proportion of patients with gametocytes  
 gametocyte clearance time (defined as for parasite clearance time) 
Safety outcomes were:  
 adverse events, categorized using MedDRA (version, 10.1) 
 laboratory abnormalities graded using the Division of Microbiology and 
Infectious Diseases Toxicity Scale (February, 2003) 
 ECG abnormalities. 
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Visit Schedule  
The study was organized in a baseline assessment, a treatment period and a 
follow-up period (Table 2). 
Baseline assessment (Day 0). Baseline examination was done within 12 hours 
before the first dose of study medication. The informed consent was obtained 
prior to any study related activity or evaluation. After having performed a blood 
smear for two thick blood smears and two thin blood smears, blood spot on filter 
paper for polymerase chain reaction analysis (PCR), physical examination, vital 
signs, laboratory tests, and electrocardiography (ECG) the patient could be 
included according to the inclusion and exclusion criteria. 
 
Treatment period (Day 0 – Day 3). The treatment period started with the first 
administration of the study medication, defined as “Day 0 hour 0”. Starting from 
hour 0 on, every 8 hours two thick blood smears were done and temperature 
was measured. Vital signs clinical signs and symptoms of malaria assessment 
and physical examination were done every 24 hours (Days 1, 2 and 3). ECG 
was done within 2-4 hours after third dose of pyronaridine or fifth of Coartem® 
(day 2). At day 3 were also performed laboratory tests.  
 
Follow up period (Day 4 – Day 42). Follow-up visits at the were done on Day 7 
(+/-1), 14(+/-1), 21(+/-1), 28(+2), 35(+/-2) and 42(+/-2) On all follow up visits two 
thick blood smears, one thin smear and blood sample on filter paper for PCR 
analysis were performed and vital signs and temperature taken. Follow up visits 
on Day 7 included in addition a physical examination and laboratory tests. Day 
28 visits required an additional physical examination as well as a haematologic 
assessment. 
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Table 2 Visit schedule for baseline, treatment and follow-up period 
a) In females of childbearing potential 
b) Every 8 hours over at least 72 hours following first study drug administration or temperature normalization for at least two readings between 8 and 24 hours apart, (when dosing and assessments 
coincided, assessments was done before dosing), then at each visit and as clinically indicated 
c) Haematology mandatory on Day 28 
d) If clinical abnormalities were observed 
e) Thick blood films were examined every 8 hours until at least 72 hours or until 2 negative smears had been recorded for at least between 8 hours and 24 hours apart (when dosing and assessments 
coincided, assessments were done before dosing); then at Day 3, 7, 14, 21, 28, 35 and 42 or any other day if the patient returned. 
f) As a reserve sample for PCR to assess status of recrudescence or re-infection in case of re-appearing parasitaemia 
g) Samples for pyronaridine and artesunate levels were taken for population PK at selected sites and selected time points (two time points per patient). 
h) A sample of blood for pyronaridine levels was taken in the event of treatment failure 
i) Thin blood films taken from Day 7 whenever parasitological blood samples were taken, and reserved in the event of recrudescence, to confirm Plasmodium species
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All patients and respective guardians were asked to present at the study center 
in case of any new or worsening disease or injury occurring in-between the 
scheduled visits. 
The following events were considered withdrawal criteria and sufficient reason 
to discontinue the study treatment: 
1. Adverse event(s) of such a nature or intensity which withdrawal was 
advisable (including abnormal laboratory findings) 
2. Vomiting as described in study drug administration 
3. Protocol violation 
4. Patient withdrawal of consent 
5. Lost to follow up  
6. Death 
If the patient discontinued study treatment before Day 3 and/or observation 
before Day 28, every effort was made to get follow up information on the status 
of the patient. The only events considered as sufficient reasons for a patient to 
discontinue observation in the clinical study were loss to follow up, death, and 
withdrawal of consent. 
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3.6 Efficacy Assessments 
3.6.1 Parasitologic Assessments 
Microscopy 
Parasite density, expressed as the number of parasites per microliter (μl) of 
blood, was measured serially to determine parasite clearance time (PCT). 
Asexual parasite and gametocyte counts were recorded separately throughout 
the study by means of finger prick. 
Blood smears preparation, staining, examination and interpretation were in 
accordance with the WHO guidelines [88]. Briefly, thick blood smear for initial 
screening was examined by counting the asexual parasites and the white blood 
cells in a limited number of microscopic fields. Parasite density was then 
calculated by counting the number of asexual parasites against a set number of 
white blood cells (WBCs) — typically 200 or 300 — in the thick blood film, using 
a hand tally counter. Once a field was started, it was counted to completion. If 
more than 500 parasites were counted before 200 WBCs were reached, the 
count was stopped after the reading of the last field was completed. Parasite 
density, expressed as the number of asexual parasites per microliter (μl), was 
calculated by dividing the number of asexual parasites by the number of WBCs 
counted and then multiplying by an assumed WBC density (typically 6000–8000 
WBCs/μl). The same technique was employed for establishing parasite counts 
on each of the subsequent blood film examinations. When the number of 
asexual parasites dropped below 10 per 200 WBCs, counting was done against 
at least 500 WBCs (i.e. to the completion of the field in which the 500th WBC 
were counted). A blood slide was considered negative when the examination of 
100 thick-film fields did not show the presence of asexual parasites. The 
presence of gametocytes on any enrolment or follow-up slide should was noted. 
In addition, 100 fields of the second thick film were examined to exclude mixed 
infections; in case of any doubt, the thin film was examined for confirmation. If 
examination of the thin film was not conclusive, the patient was excluded from 
the study after complete treatment.  
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Thick and thin blood films for parasite count was obtained and examined at 
screening on Day 0 to confirm inclusion/exclusion criteria. Thick blood films 
were examined every 8 hours (+/- 1 hour) following first dose administration and 
for at least 72 hours or until the parasites had cleared as evidenced by two 
consecutive negative readings taken 8 to 24 hours apart. Microscopy was 
conducted before any dose of clinical trial medication on each of the first three 
days, or until parasites had been cleared as defined above. Thick blood films 
were also examined on Days 3, 7, 14, 21, 28, 35 and 42 or on any other day if 
the patient spontaneously returned. Additionally, blood films were obtained 
whenever parasitological reassessment was required. A thin blood smear was 
also taken from Day 7 whenever parasitological blood samples were taken and 
kept in the event of recrudescence, to confirm Plasmodium species. 
Local quality control of slides was assured by reading of slides by 2 different 
qualified microscopists, reporting independently, with the arithmetic mean of the 
2 counts. In the case of discrepancy, a third microscopist reviewed. An external 
quality control of slide reading was established by an independent laboratory at 
Swiss Tropical Institute (STI), Basel, Switzerland. The external quality control 
was blinded to treatment assignment. STI examined all slides in the case of 
suspected recrudescence plus a proportion of slides from each study site. 
 
3.6.2 Genotyping Studies by PCR 
Genotyping studies by PCR were used to differentiate new infection from 
recrudescence. Samples were taken for PCR assessment prior to initial dosing 
on Day 0. Blood samples were added directly from finger pricks to FTA Cards. 
PCR samples were also taken from Day 7 at each study visit and whenever 
parasitological blood samples were taken, and preserved. The PCR analysis 
was performed in the case of reappearance of parasites as judged by a positive 
microscopy slide. PCR samples were shipped by courier for centralized 
assessments at the Swiss Tropical and Public Health Institute (Basel, 
Switzerland) and PCR genotyping using P. falciparum glurp, msp1 and msp2 
genes was then performed at the central laboratory in Basel [89]. Briefly, a 
small FTA-card disk was punched out of the dried blood spot of the FTA card 
Methods 
 
31 
and washed extensively with DNA purification solution. After washing with 
ethanol the disks were dried. A nested PCR was conducted for the msp2 locus 
using primary primers (S2: 5'- GAA GGT AAT TAA AAC ATT GTC -3'; S3: 5'- 
GAG GGA TGT TGC TGC TCC ACA G -3') with the following PCR conditions: 
30 cycles of (94ºC - 5 min 94ºC - 30 sec 42ºC - 1 min, 65ºC - 2 min). Nested 
PCR was conducted with nested primers S1: 5'- GAG TAT AAG GAG AAG TAT 
G -3'; S4: 5'- CTA GAA CCA TGC ATA TGT CC -3'. PCR working conditions 
are 30 Cycles of (94ºC - 5 min 94ºC - 30 sec 50ºC - 1min 70ºC - 2 min). After 
PCR the amplified DNA was digested with the restriction endonuclease HinfI 
and subsequently run on a 1.5% agarose gel. The gel was electronically 
documented using an Omnilab Gel Documentation system. 
Samples showing a banding pattern different from the banding pattern of Day 
0/Day 1 were considered as new infections and no further analysis was 
required. Samples which show a banding pattern identical to the banding 
pattern on Day 0/Day 1 or show a banding pattern which contains identical 
alleles observed at Day 0/Day 1 were considered as potential recrudescence 
and were processed further. Identical alleles were further discriminated by size 
and by allelic family using the following PCR conditions: Primers for primary 
PCR: M1-OF and M1-OR M1-OF: 5'-CTA GAA GCT TTA GAA GAT GCA GTA 
TTG-3'; M1-OR: 5'-CTT AAA TAG TAT TCT AAT TCA AGT GGA TCA-3'; with 
the following PCR conditions: 25 Cycles  of (94ºC - 5 min 94ºC - 30 sec 55ºC - 
1 min  70ºC - 2 min). Family specific nested PCRs will be set up with the 
following primers: K1 allelic family: M1-KF and M1-KR: M1-KF: 5'-AAA TGA 
AGA AGA AAT TAC TAC AAA AGG TGC-3'; M1-KR: 5'-GCT TGC ATC AGC 
TGG AGG GCT TGC ACC AGA -3'; MAD20 allelic family: M1-MF and M1-MR 
M1-MF: 5'-AAA TGA AGG AAC AAG TGG AAC AGC TGT TAC-3'; M1-MR: 5'-
ATC TGA AGG ATT TGT ACG TCT TGA ATT ACC -3'; RO33 allelic family: M1-
RF and M1-RR M1-RF: 5'-TAA AGG ATG GAG CAA ATA CTC AAG TTG TTG-
3'; M1-RR: 5'-CAT CTG AAG GAT TTG CAG CAC CTG GAG ATC -3' with the 
following PCR conditions 30 Cycles of (94ºC - 5 min 94ºC - 30 sec 58ºC - 1 min 
70ºC - 2 min). 
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After PCR the samples were run on a 1.5% agarose gel and documented as 
above. Recurrent samples with identical banding patterns as on Day 0/Day 1 or 
with banding patterns contained in samples from Day 0/Day 1 were considered 
as true recrudescence and were documented as treatment failures. 
Recrudescence was then defined as one or more superposable allelic bands in 
all three markers between samples from Day 0/Day 1 and samples obtained 
after Day 7. Completely different patterns were classified as new infections. 
 
3.6.3 Clinical Efficacy Assessments  
Body Temperature 
Temperature was measured at screening on Day 0 (Pre-Dose) and every 8 
hours over at least 72 hours following first study drug administration or when the 
temperature had normalized (less than 38.0°C oral/tympanic/rectal at readings 
taken between 8 and 24 hours apart). Temperature was measured at every visit 
thereafter and as clinically indicated. When the time of study drug administration 
and clinical assessments coincided on Day 2 and Day 3, the clinical 
assessment was performed before the study drug administration. Temperature 
methodology was according to local practice. Within an individual patient the 
same means of temperature measurement (oral, tympanic or rectal) were used 
throughout the entire study period. Patients who have had a documented 
reported history of fever (more than 38.0°C oral/tympanic/rectal) prior to 
screening were monitored closely for fever peaks. 
Patients entered in the study on the basis of history of fever and who did not 
subsequently have at least one body temperature measurement indicating 
presence of fever were not included in the analysis of fever clearance time. 
Quality of temperature-taking technique and thermometers were checked and 
calibrated prior to study commencement and at regular intervals during study. 
 
Clinical Signs and Symptoms 
Clinical signs and symptoms of malaria were assessed during the treatment 
period, plus on any other occasion where the patient presented to the site, 
when clinically indicated. The following signs and symptoms were specifically 
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assessed: rigors/chills, sweating, headache, nausea, vomiting, cough, loss of 
appetite/anorexia, fatigue (asthenia/lethargy/malaise), myalgia (back and limbs), 
jaundice (hyperbilirubinaemia), hepatomegaly and splenomegaly. If the signs or 
symptoms of acute malaria represented a clinically significant worsening 
compared to the patient’s baseline condition, and were considered to be more 
severe than normal daily fluctuation of the disease process, then this was 
recorded as an adverse event. 
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3.7 Safety Assessments 
Safety was assessed using the following criteria: 
  Nature, incidence, relationship and severity of Adverse Events (AEs) 
and Serious Adverse Events (SAEs). Adverse event reporting was 
assessed through indirect questioning. 
 Clinically significant change from baseline clinical laboratory parameters.  
 Incidence of and reasons for withdrawals. 
 Physical examinations and vital signs. 
 12-Lead ECG assessments. 
 
3.7.1 Clinical Safety Assessments 
Clinical evaluations were undertaken in all patients using the following 
parameters: 
 
Physical Examination 
A standard physical examination was performed at baseline (Day 0 pre-dose), 
as well as on Day 1, 3 and 28, and in case of early termination. At a minimum 
the following body systems were examined: general appearance; head and 
eyes; ears, nose and throat; chest and lungs; cardiovascular; abdomen; 
neurological; lymphatic and musculoskeletal. A complete medical history, 
demography, and contact address and details were also taken at baseline. 
 
Body Weight and Height 
Body weight and height were recorded at screening on Day 0 (pre-dose). The 
screening weight was used to satisfy the inclusion/exclusion criteria for 
minimum weight as well as to calculate the dose to be administered. The 
reliability of weighing scales was verified prior to commencement of study and 
was checked and documented at regular intervals during the study.  
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Vital Signs 
Vital signs (supine blood pressure and heart rate) were taken after the patient 
had been supine for 5 minutes. Vital signs were measured at baseline (Day 0 
pre-dose) and on Day 1, 2, 3, 7, 14, 21, 28, 35 and 42 and in the case of early 
termination. In addition, vital signs could be measured during the study period, 
as clinically indicated. 
 
3.7.2 Laboratory Assessments 
Clinical laboratory tests were performed as indicated in Table 3. Haematology 
parameters were measured on Day 0, Day 3, Day 7 and Day 28, as well as Day 
42 if clinically indicated (e.g., presence of anemia at Day 28). Biochemistry and 
urinalysis were measured on Day 0, Day 3, and Day 7, as well as Day 28 and 
42 if clinically indicated. Female patients of child-bearing potential had a urine 
hCG test for pregnancy prior to inclusion and on Day 28 and 42. Clinical 
laboratory tests required 2 ml for haematology and 2 ml for clinical chemistry, 
plus a urine sample for dipstick analysis.  
 
Table 3. Clinical laboratory tests performed 
Haematology 
Haematocrit 
Haemoglobin 
Erythrocyte count (RBC) 
Platelet count 
 
Leukocytes (WBC) with differential count 
including eosinophils 
Reticulocytes 
Clinical chemistry 
Total bilirubin 
Albumin 
Alanin aminotransferase 
Aspartate aminotranferase 
Creatin kinase 
 
Alkaline phosphatase 
Urea 
Creatinine 
 
Sodium 
Potassium 
Glucose 
 
Pregnancy test (urine hCG)* 
*Females with childbearing potential 
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3.7.3 ECG 
The incidence and nature of clinically significant ECG abnormalities were 
assessed. A 12-lead resting ECG was obtained at screening on Day 0 (Pre-
Dose), and approximately 2 - 4 hours after study drug administration on Day 2. 
An ECG was performed also on Day 7, 14 or 28 if clinically significant 
abnormalities were observed. Further ECG measurements at other times could 
be taken if clinically indicated. Clinical indications for further ECG recordings 
could be the finding of obvious abnormalities of rhythm, and/or obvious changes 
from the previous ECG or if the patient experienced cardiac-type symptoms 
such as chest pain, palpitation or shortness of breath. Only one recording was 
required, however after the recording was made on each occasion the ECG 
was inspected to ensure that it was of sufficient quality for interpretation (i.e. all 
of the leads were in their correct place and there was minimum artifact). The 
ECG recording was read and interpreted by the Investigator. A proportion of 
ECGs were sent to a central blind reviewer (at Fulcrum Pharma) for review.  
The ECG was reviewed for: 
1. Waveforms P, QRS and T as well as the presence of U waves. 
2. Rhythm (abnormal rhythms as well as tachycardia and bradycardia). 
3. Evidence of abnormalities of PR, QT, and ST segments. 
4. An assessment of overall “normality” of the ECG and where borderline or 
abnormal whether the abnormality is clinically significant. 
5. Any change from baseline or from one ECG to the next. 
6. Where an ECG was considered abnormal at baseline consideration as to 
whether an exclusion criterion has been violated needed to be considered.  
7. Where an ECG exhibited a change this needed to be recorded and clinical 
significance assigned (Yes/No); if clinically significant then an AE was recorded 
if appropriate.  
 
  
Methods 
 
37 
3.8 Adverse Events 
3.8.1 Adverse Event Definition 
The following definitions were employed for the reporting of adverse events: 
A) Adverse Event 
An adverse event was defined as any unfavorable and unintended sign, 
symptom, syndrome, or illness that develops or worsens during the period of 
observation in the clinical study. Clinically relevant abnormal results of 
diagnostic procedures including abnormal laboratory findings (e.g., requiring 
unscheduled diagnostic procedures or treatment measures, or resulting in 
withdrawal from the study) which were considered by to be detrimental were 
recorded as adverse events whether or not they had a causal relationship with 
the study drug. Where the laboratory result was a sign of another clinical 
condition, the clinical condition itself was the reported adverse event. An event 
unequivocally caused by a significant deterioration of the underlying condition 
related to malaria was regarded as an adverse event. Recrudescence or new 
infection during the course of the study was not reported as adverse event 
unless the resulting malaria was of an unexpected severity. 
B) Unexpected Adverse Event 
Any adverse experience that had not been previously observed, (i.e. included in 
the protocol), whether or not the event was anticipated because of the 
pharmacologic properties of the study drug. 
C) Serious Adverse Event 
Any adverse experience occurring at any dose that resulted in any of the 
following outcomes: 
 Death 
 Life threatening defined as an experience that placed the patient at risk 
of death at the time of the event.  
 Required inpatient hospitalization or prolongation of existing 
hospitalization. 
 Resulted in a congenital anomaly or birth defect. 
 Resulted in a persistent or significant disability or incapacity. 
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 Important medical events that did not result in death, were life-
threatening or required hospitalization were considered as a serious 
adverse drug experience when, based upon appropriate medical 
judgment, they jeopardized the patient and required surgical or medical 
intervention to prevent any of the above-listed outcomes. 
The following were not considered as serious adverse events: cases of 
hospitalization for elective surgery, need to observe high risk patients to prevent 
serious events, and visiting the emergency room due to suffering from adverse 
events but discharged after treatment without hospitalization. 
 
D) Alert terms and other reasons for expedited reporting to Pharmacovigilance. 
No specific events were subject to reporting as alert terms in this study.  
 
Pregnancy did not constitute an adverse event. When occurred, the pregnant 
patient had to be followed until birth of the child. However, any adverse 
outcome to the mother, fetus or newborn had to be regarded as a serious 
adverse event. Worsening of the baseline conditions that were judged to be 
more significant than normal daily fluctuation of the disease symptoms were to 
be regarded as adverse events. 
 
3.8.2 Assessment of Adverse Events 
A) Severity 
The severity/intensity of the adverse reactions and clinical laboratory changes 
were assessed using the “DMID Toxicity Grading Scale  for Determining the 
Severity of Adverse Events” [90]. 
If an adverse event was not listed in the DMID table, the severity was assessed 
using the following guidelines: 
1 = Mild: awareness of sign or symptom, but easily tolerated 
2 = Moderate: enough discomfort to cause interference with usual activity 
3 = Severe: incapacitating with inability to work or do usual activity 
4 = Life-Threatening  
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B) Relationship or Association with the Use of Study Drug or Study Procedure 
The relationship was between an event and the study drug was assessed using 
the following guidelines and terminology: 
Definite: clear-cut temporal association, with a positive re-challenge test or 
laboratory confirmation. 
Probable: clear-cut temporal association, with improvement upon drug 
withdrawal, and not reasonably explained by the patient’s known clinical state. 
Possible: less clear temporal association; other etiologies are possible. Other 
possible etiologies were recorded on the CRF. 
None: no temporal association with the study drug; related to other etiologies 
such as concomitant medications or conditions, or subject’s known clinical 
state. 
C) Action Taken 
- Study drug discontinued 
- Patient withdrawn from study 
- Concomitant Medication required 
- Hospitalization required or prolonged (this was to be reported as a serious 
adverse event 
- Other 
D) Outcome 
The patient was followed until AE resolution or until no further medically 
relevant information could be expected. AE outcome was classified as follows: 
• Resolved 
• Resolved with sequelae 
• Continuing 
• Death 
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3.9 Analytical and Statistical Plan 
The Intention-To-Treat (ITT) population included all randomized subjects who 
received any study antimalarial medication. The Safety population was 
considered the same as the ITT-population. The Per-Protocol (PP) population 
was defined as all patients receiving a full course of study medication with 
recorded primary endpoint on Day 28 and had no protocol deviation/violation 
that could impair evaluation of Day 28 primary endpoint. The Efficacy Evaluable 
(EE) population included all patients receiving a full course of study medication 
and had a known 28 and/or 42 efficacy endpoint. Cure rates were also 
calculated for the ITT population employing an extreme case scenario. All 
patients who received any amount of study medication and who were not 
evaluable on Day 28 were considered as treatment failures. 
The exact binomial test was used to evaluate the primary efficacy endpoint in 
the PP population (significance limit ≤ .025). The associated exact (Pearson–
Clopper) two-sided 95% confidence interval (CI) was calculated (Graphpad 
Prism 6.0).  
In order to evaluate the main secondary efficacy endpoint in the PP population, 
pyronaridine-artesunate was considered as non-inferior to artemether-
lumefantrine when the lower limit of the two-sided 95% confidence interval for 
the difference between treatments was not lower than −10 % (Newcombe-
Wilson score method without continuity correction [91, 92], Graphpad Prism 
6.0). The non-inferiority margin of 10% was primarily specified for the total 
patient population of the study, as with 480 evaluable patients (randomized 2:1) 
the secondary endpoint of non-inferiority of pyronaridine-artesunate would be 
demonstrated with >99% power [76]. The analysis was repeated for the ITT 
population (extreme case scenario), Day 28 crude ACPR, Day 14 and Day 42 
PCR corrected and crude ACPR. A post-hoc Kaplan-Meyer analysis of parasite 
clearance in the Efficacy Evaluable population was conducted. Treatments were 
compared by using the log-rank test. Kaplan–Meyer analysis and log-rank were 
also used to compare fever clearance between treatments (Graphpad Prism 
6.0).  
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3.10 Patient Confidentiality 
The CRF as well as all reports and communications relating to patients in the 
study identified each patient only by the patient’s initials (first, middle, last) and 
by the patients’ identification number. The investigator maintained a current 
confidential Patient Identification Code List of names of all patients allocated to 
patient identification numbers in this study. This list allowed the investigators to 
reveal the identity of the patients in the event that they needed to be contacted 
for safety reasons. This information was held in the strictest confidence and was 
used only for emergency purposes, if needed.  
 
3.11 Ethics and Good Clinical Practice 
The protocol and informed consent were reviewed and approved by the Ethics 
Committee of the International Foundation of the Albert Schweitzer Hospital 
before the study was initiated. The study was carried out in compliance to the 
protocol, in accordance with the Declaration of Helsinki and in adherence to 
Good Clinical Practice guidelines [93]. 
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4 Results 
_______________________________________________________________ 
4.1 Study Flow 
The study took place from the 4th October 2007 to the 5th September 2008 
comprising a total of eleven months. From 134 children and infants presenting 
at the study site with fever or/and history of fever and a positive thick smear for 
P. falciparum, 80 children were enrolled after screening procedures into the 
present study. The exclusions were mostly due to low haemoglobin (<8 g/dl), 
low parasitaemia (<1000 parasites/mL), high parasitaemia (>200,000 
parasites/μl), prior antimalarial treatment, liver function over 2.5 times ULN 
range, severe vomiting and lack of parents' willingness to comply with all 
planned visits until Day 42. All patients not included in the study received 
medical assistance and treatment according to the clinical guidelines of the 
hospital. 
After randomization procedures, 53 recruited subjects were enrolled in the 
pyronaridine-artesunate treatment group and 27 patients in the artemether-
lumefantrine treatment group. All of the participants finished the 3 days 
treatment regimen and were included in the ITT population and in the Safety 
population. Three subjects in the pyronaridine-artesunate group did not finish 
the 42-days follow-up period. The early withdrawal of the participants in the 
pyronaridine-artesunate group was due to reappearance of parasites on Day 28 
(two cases) and consent withdrawn on Day 14 (one case). Two participants in 
the pyronaridine-artesunate group and one in the artemether-lumefantrine 
group had reappearance of parasites on Day 42. All patients with reappearance 
of parasites received rescue medication with ACT according to the clinical 
guidelines (artemether–lumefantrine or artesunate-amodiaquine in the case of 
prior artemether-lumefantrine). Therefore, 79 (52 and 27, respectively) 
participants comprised the PP population on Day 28 and 77 patients were 
included in the EE population (50 and 27 participants, respectively) on Day 42. 
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Figure 1. Study flow 
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4.2 Demographic and Baseline Characteristics 
Demographic and clinical characteristics at baseline of the ITT-population (all 
randomized subjects who received any study antimalarial medication) are 
shown in Table 4. Baseline clinical and demographic characteristics were 
comparable within the two treatment groups, as no significant differences were 
found. It is important to notice that no patient under 1 year was included in any 
group. Regarding laboratory findings, no differences were found with respect to 
baseline parasitaemia (asexual forms) as well as percentage of patients 
presenting gametocytes at baseline.  
Haematology and biochemistry values were representative for children with 
acute uncomplicated P. falciparum malaria (Tables 14 and 15).  Mean 
haemoglobin values were below normal range in both treatment groups, 10 g/dl 
in the pyronaridine-artesunate group and 10.2g/dl in the artemether-
lumefantrine group. Platelets were also below normal range at baseline 
179000/µl and 201000/µl respectively. Baseline mean values of albumin, total 
bilirubin, ALT, urea, creatinine, glucose, sodium and potassium were within 
normal ranges. Mean values of AST were slightly over normal range at 
baseline. None of the patients had any clinically significant ECG finding at 
baseline. 
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Table 4. Baseline characteristics 
 
Pyronaridine-
artesunate 
n=53 
Artemether- 
lumefantrine 
n=27 
Gender M/F % 53/47 46/54 
Age, months Mean (SD) 56 (26) 55(29) 
Age category n (%) 
<1 year 
1-5 years 
5-12 years 
0 (0) 
34 (64%) 
19 (36%) 
0 (0) 
17 (63%) 
10 (37%) 
Height, cm Mean (SD) 101 (15) 105 (18) 
Weight, kg Mean (SD) 15.7 (3.9) 16.7 (4.5) 
Asexual forms/μl 
Median (range) 
25408 
(1343 -170313) 
23601 
(1248 – 133839) 
Patients with gametocytes n (%) 4 (8%) 3 (11%) 
Fever at baseline n (%) 30 (57%) 15 (56%) 
Temperature Mean (SD) 37.8 (0.9) 37.8 (1.1) 
Malaria in last 12 months 
None 
1 
2 
>2 
 
25 (47%) 
18 (34%) 
7 (13%) 
3 (6%) 
 
12 (45%) 
10 (37%) 
2 (11%) 
2 (7%) 
Showing main clinical, demographic and parasitological baseline characteristics in the 
ITT population (gender, age, weight, height, parasitaemia, fever, mean temperature 
and previous malaria episodes <12 months). All findings were comparable between 
both treatment groups. 
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4.3 Efficacy 
Efficacy measures were evaluated for the ITT population and the EE population.  
4.3.1 Primary Efficacy Endpoint 
PCR-corrected ACPR >90% at Day 28 
The primary outcome of this study was achieved. The cure rate at Day 28 
(PCR-corrected ACPR >90%) served as primary outcome measure of efficacy 
in this clinical trial. In the EE population all patients were clinically and 
parasitologically cured on Day 28 (clearance of asexual parasitaemia within 72 
hours and without subsequent PCR-corrected recrudescence within 28 days). 
PCR-corrected ACPR in the EE population was therefore 100% (52/52) with a 
95% CI of 93 to 100%, and statistically significantly above 90% (p-value= 0.009; 
Table 5, Figure 2). Cure rates were also calculated for the ITT population 
employing an extreme case scenario (all patients who received any amount of 
study medication and who were not evaluable on Day 28 were considered as 
treatment failures). The intention-to-treat analysis was therefore supportive of 
the primary analysis, with a PCR-corrected ACPR of 98.1% (95% CI 90-99.9), 
p-value = 0.026). 
 
Table 5. Primary endpoint  
Day 28 PP population ITT population 
Day 28 PCR-corrected APCR (n/N) 
percentage 
52/52 
100% 
52/53 
98.1% 
95% CI 93-100% 90-99.9% 
p-value (binomial exact test) 0.009 0.026 
Table 5. Cure rate (adequate clinical and parasitological response) at Day 28 PCR-corrected in 
the PP and ITT population.  
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Figure 2. PCR-corrected ACPR on Day 28 
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Comparison of PCR corrected-ACPR on Day 28 between pyronaridine-
artesunate (PA) and artemether-lumefantrine (AL) treatment groups in both PP 
and ITT populations. Both treatments showed >90% of cure rate. 
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4.3.2 Secondary Efficacy Endpoints 
Non-inferiority of Day 28 PCR-corrected ACPR  
The Day 28 PCR-corrected ACPR rate of the pyronaridine-artesunate group 
was comparable to that of the artemether-lumefantrine group, in both PP (100% 
versus 100%; treatment difference 0, 95% CI: -6.9 to 12.5) and ITT population 
(98.1% versus 100%; treatment difference -1.9, 95%CI: -9.9 to 10.7). The main 
secondary endpoint, non-inferiority of pyronaridine-artesunate compared to 
artemether-lumefantrine, was thus concluded for Day 28 PCR-corrected ACPR. 
However, as the lower limit of the 95% CI between difference was <10% in both 
PP and ITT populations (-6.9 and 12.5 respectively), non-inferiority was not 
demonstrated for Day 28 crude ACPR (PP population: difference -3.9, 95% CI: -
12.9 to 8.9; ITT population difference -5.7, 95% CI: -15.3 to 7.4). It is important 
to note that the non-inferiority margin was primarily specified for the total patient 
population of the multicentre study (n=480). 
 
Table 6 Comparison of ACPR rates between treatment groups on Day 28 
Day 28 Pyronaridine - 
artesunate  
Artemether -
lumefantrine 
Difference 
(95% CI) 
PCR- corrected ACPR (PP)  52/52 
100% 
27/27 
100% 
 
0 (-6.9 to 12.5) 
PCR- corrected ACPR (ITT)  52/53 
98.1 
27/27 
100% 
 
-1.9 ( -9.9 to 10.7)  
crude ACPR (PP) 50/52 
96.1% 
27/27 
100% 
 
-3.8 ( -12.9 to 8.9)  
crude ACPR (ITT) 50/53 
94.3 
27/27 
100% 
 
-5.7 (-15.4 to 7.4) 
Non-inferiority analysis of pyronaridine-artesunate versus artemether-lumefantrine, 
concluded on Day 28 for PCR-corrected ACPR for both PP and ITT populations. 
Considered when the lower limit of the difference between cure rates >-10%.  
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Figure 3. Crude and PCR-corrected ACPR comparison between treatment 
groups in A) PP population and B) ITT population  
 
A 
0
2 5
5 0
7 5
1 0 0
PA
9 6 .1 %
A L
1 0 0 %
P e r -p r o to c o l p o p u la t io n
P C R - c o rre c te d  A C P R
PA
1 0 0 %
A L
1 0 0 %
C
u
r
e
 r
a
te
 (
%
)
C ru d e - A C P R
 
B 
0
2 5
5 0
7 5
1 0 0
PA
9 4 .3 %
A L
1 0 0 %
In te n tio n -to -tre a t p o p u la tio n
P C R - c o rre c te d  A C P R
PA
9 8 .1 %
A L
1 0 0 %
C
u
r
e
 r
a
te
 (
%
)
C ru d e - A C P R
 
Non-inferiority analysis of pyronaridine- artesunate against artemether-
lumefantrine. Concluded for PCR-corrected ACPR in both PP (3A) and 
ITT (3B) populations.  
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Day 14 and Day 42 crude and PCR-corrected ACPR 
Day 14 crude and PCR-corrected ACPR rates were 100% for the EE and ITT 
population in both treatment groups. The lower limit of 95% CI of the difference 
was >10% in both analysis and no significant differences between treatments 
were found (lower limit of 95% CI of the difference: 6.8). Day 42 PCR-corrected 
ACPR rates were 100 % in pyronaridine-artesunate and 100% in artemether-
lumefantrine in the EE population while in the ITT population (extreme case 
scenario) the ACPR rates were 94.3% and 100% respectively. The crude ACPR 
cure rates were 96% and 96.3% in the EE population and 90.6% and 96.2% in 
the ITT population. Non inferiority was demonstrated for Day 42 PCR–corrected 
ACPR in the pyronaridine-artesunate group with a lower 95% CI of the 
difference against artemether-lumefantrine of -7.1. 
Table 7. Comparison of ACPR rates between treatment groups on Day 14 and 
Day 42 
 Pyronaridine-
artesunate  
Artemether-
lumefantrine 
Difference 
(95% CI) 
Day 14 crude ACPR 
EE 
ITT 
 
53/53(100%) 
53/53(100%) 
 
27/27(100%) 
27/27(100%) 
 
0 (-6.8 to 12.5) 
0 (-6.8 to 12.5) 
Day 14 PCR-corrected ACPR 
EE 
ITT 
 
53/53(100%) 
53/53(100%) 
 
27/27(100%) 
27/27(100%) 
 
0 (-6.8 to 12.5) 
0 (-6.8 to 12.5) 
Day 42 Crude ACPR 
EE 
ITT 
 
48/50(96.0%) 
48/53(90.6%) 
 
26/27 (96.3%) 
26/27 (96.2%) 
 
-0.3 (-10.2 to14.6) 
-6.2 (-16.9 to 9.6 ) 
Day 42 PCR-corrected ACPR 
EE 
ITT 
 
50/50 (100%) 
50/53 (94.3%) 
 
27/27 (100%) 
27/27 (100%) 
 
0 (-7.1 to12.6) 
-5.7(-15.4 to 7.3 ) 
Non-inferiority analysis, pyronaridine-artesunate versus artemether-lumefantrine on 
day 14 and 42 (crude and PCR-corrected ACPR, EE and ITT populations). Non 
inferiority was demonstrated on Day 14 for both crude and PCR-corrected ACPR and 
for PCR-corrected ACPR on Day 42 for EE population. Non-inferiority was defined as a 
lower limit of the difference between cure rates greater than -10%. 
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4.3.3 Parasite Clearance Time 
Parasite clearance time was evaluated in the EE (PP) population. Median time 
to parasite clearance was significantly shorter in patients treated with 
pyronaridine-artesunate (23.9 h; 95% CI 17.0-24.1) compared to artemether-
lumefantrine (24 h; 95% CI 23.9-31.8; p-value =0.036, log-rank test; Figure 3). 
Moreover, percentile-25 time to parasite clearance was 16h in the pyronaridine-
artesunate group and 23h in the artemether-lumefantrine group, while 
percentile-75 times were 31.9h and 32h, respectively. 
 
Figure 4.  Parasite clearance time 
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Parasite clearance time in EE population, showing significant shorter clearance in 
patients receiving pyronaridine-artesunate 
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4.3.4 Fever Clearance Time 
Fever clearance time was evaluated in the PP population having fever at 
baseline. Fever was present in 55% (39/53) of the subjects receiving 
pyronaridine-artesunate while 56% (15/27) of the patients receiving artemether-
lumefantrine had fever at baseline. Median fever clearance time was not 
significantly different between pyronaridine-artesunate (11.5 h; 95% CI: 8-16 h) 
versus artemether-lumefantrine (9.5 h; 95% CI: 8-24 h; p-value = 0.69, log rank 
test; Figure 5). Percentile-25 time to fever clearance was 8h for both 
pyronaridine-artesunate and artemether-lumefantrine, while the percentile-75 
was 23.9 and 16.4, respectively.  
 
Figure 5. Fever clearance time  
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Fever clearance time in EE population. No significant differences were found between 
treatment groups 
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4.3.5 Percentage of Patients with Gametocytaemia 
Gametocytaemia at baseline as well as the percentage of patients cleared from 
gametocytes were evaluated on Day 3, 7, 14, 21, 28 and 42 (Table 8). At 
baseline, 9% (7/80) of the total included patients had gametocytes, 8% (4/53) in 
the pyronaridine-artesunate group and 11% (3/27) patients in the artemether-
lumefantrine group. Patients with observed gametocytes at any point of the 
study were 17% (9/53) in the pyronaridine-artesunate and 22% (6/27) in the 
artemether-lumefantrine group. New appearance of gametocytaemia in patients 
that had none at baseline was found in 9.4% (5/53) of patients receiving 
pyronaridine-artesunate and in 11% (3/27) of those receiving artemether-
lumefantrine. In the pyronaridine-artesunate group, complete gametocyte 
clearance was accomplished between Day 21 and Day 28 while patients in the 
artemether-lumefantrine group achieved clearance between Day 7 and 14. 
 
Table 8.  Patients with gametocytes over the course of the study 
 Pyronaridine-
artesunate 
Artemether-
lumefantrine 
Patients with 
   gametocytes at baseline                 n (%) 
   gametocytes at any time-point        n (%) 
   gametocytes post-baseline             n (%) 
 
4 (8%) 
9 (17%) 
5 (9%) 
 
3(11%) 
6(22%) 
3(11%) 
Gametocytaemia (sexual forms/µl)* 
  Median (Min-Max) 
 
76 (53 – 217) 
 
95 (17 – 289) 
Patients with gametocytes                  n (%) 
  Baseline  
  Day 0-3 
  Day 7 
  Day 14 
  Day 21 
  Day 28 
  Day 35 
  Day 42 
 
4 (8%) 
9 (17%) 
6 (11%) 
3 (6%) 
1 (2%) 
0 
0 
0 
 
3 (11%) 
6 (22) 
1 (4%) 
0 
0 
0 
0 
0 
Number of patients with gametocytes at baseline, baseline gametocytaemia (defined 
as numbers of P. falciparum sexual forms per microliter of blood), and percentage of 
patients cleared from gametocytes. 
*measured in patients showing gametocytes already at baseline 
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Table 9. Summary of the efficacy analysis 
 
Outcome 
Efficacy Evaluable population Intention-To-Treat  population 
Pyronaridine-
artesunate 
Artemether-
lumefantrine 
Difference     
(95% CI) 
Pyronaridine-
artesunate 
Artemether-
lumefantrine 
Difference     
(95% CI) 
Day 14 PCR-corrected ACPR 53/53 27/27 0(-6.8 to 12.5) 53/53 27/27 0 (-6.8 to 12.5) 
% (95% CI) 100 (93.3-100) 100 (87.2-100)  100 (93.3-100) 100 (87.2-100)  
Total failures 
Early treatment failure 
Late clinical failure 
Late parasitological failure 
Missing considered failure 
0 
0 
0 
0 
- 
0 
0 
0 
0 
- 
 0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
 
Day 14 crude  ACPR 53/53 27/27 0(-6.8 to 12.5) 53/53 27/27 0 (-6.8 to 12.5) 
% (95% CI) 100 (93.3-100) 100 (87.2-100)  100 (93.3-100) 100 (87.2-100)  
Total failures 
Early treatment failure 
Late clinical failure 
Late parasitological failure 
Missing considered failure 
0 
0 
0 
0 
- 
0 
0 
0 
0 
- 
 0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
 
Day 28 PCR-corrected ACPR 52/52 27/27 0(-6.9 to 12.5) 52/53 27/27 -1.9(-9.9 to 10.7) 
% (95% CI) 100 (93.1-100) 100 (87.2-100)  98.1 (90.0-99.9) 100 (87.2-100)  
p- value binomial test 0.0086   0.0265   
Total failures 
Early treatment failure 
Late clinical failure 
Late parasitological failure 
Missing considered failure 
Re-appearance before Day 28 
0 
0 
0 
0 
- 
- 
0 
0 
0 
0 
- 
- 
 1 
0 
0 
0 
1 
0 
0 
0 
0 
0 
0 
0 
 
Day 28 crude  ACPR 50/52 27/27 -3.8( -12.9 to 8.9) 50/53 27/27 -5.7(-15.4 to 7.4) 
% (95% CI) 96.1(86.8-99.5) 100 (87.2-100)  94.3 (84.3-98.8) 100 (87.2-100)  
Total failures 
Early treatment failure 
Late clinical failure 
Late parasitological failure 
Missing considered failure 
2 
0 
0 
2 
- 
0 
0 
0 
0 
- 
 3 
0 
0 
2 
1 
0 
0 
0 
0 
0 
 
Day 42 PCR-corrected ACPR 50/50 27/27 0(-7.1 to12.6) 50/53 27/27 -5.7(-15.4 to 7.4) 
% (95% CI) 100 (92.8-100) 100 (87.2-100)  94.3 (84.3-98.8) 100 (87.2-100)  
Total failures 
Early treatment failure 
Late clinical failure 
Late parasitological failure 
Missing considered failure 
Re-appearance before Day 42 
0 
0 
0 
0 
- 
- 
0 
0 
0 
0 
- 
- 
 3 
0 
0 
0 
1 
2 
0 
0 
0 
0 
0 
0 
 
Day 42 crude  ACPR 48/50 26/27 -0.3(-10.2 to14.6) 48/53 26/27 -6.3(-16.9 to 9.6) 
% (95% CI) 96.0 (86.2-99.5) 96.3 (81-99.9)  90.6 (79.3-96.9) 96.3 (81-99.9)  
Total failures 
Early treatment failure 
Late clinical failure 
Late parasitological failure 
Missing considered failure 
2 
0 
0 
2 
- 
1 
0 
0 
1 
- 
 5 
0 
0 
4 
1 
1 
0 
0 
1 
0 
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4.4 Safety 
All safety analysis was performed for the safety population, which comprised all 
randomized subjects who received any study antimalarial medication. 
4.4.1 Incidence and Severity of any Adverse Event 
A total of 135 adverse events were registered during the course of the study, 76 
in the group receiving pyronaridine-artesunate and 40 in the group receiving 
artemether-lumefantrine. Experience of at least one adverse event of any cause 
occurred in 39/53 (74%) and in 21/27 (78%) patients receiving pyronaridine-
artesunate and artemether-lumefantrine, respectively (Table 3). There were no 
deaths. Neither serious adverse events leading to study-drug discontinuation 
nor withdrawal occurred in the course of the study. 
Table 11. Incidence of adverse events 
 Pyronaridine-artesunate 
n=53 
Artemether-lumefantrine 
n=27 
 n % n % 
Any AE 39 74% 21 78% 
Any drug related AE 6 11% 6 22% 
Any Serious AE 0 0% 0 0% 
Any severe or life 
threatening AE 
0 0% 0 0% 
Any Death 0 0% 0 0% 
Any AE leading to study 
drug discontinuation 
0 0% 0 0% 
Any AE leading to 
withdrawal of the study 
0 0% 0 0% 
Overall incidence and rates of adverse events in the Safety population 
 
Regarding the incidence or nature of adverse events, there were no clinically 
important differences between the two study groups (Table 12). The majority of 
the adverse events were of mild intensity. However, 6% (3/76) of the total 
reported adverse events by patients receiving pyronaridine-artesunate and 8% 
(2/40) of those reported by patients receiving artemether- lumefantrine were 
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designated as of moderate intensity. The adverse events of moderate severity 
were: fever >40°C, anaemia and blood AST/ALT increased in the pyronaridine-
artesunate group, and two cases of upper respiratory infection with fever >40°C 
in the artemether-lumefantrine group. None of the moderate adverse events 
were considered as possible related to the medication intake. All experienced 
adverse events are listed below in Table 12. 
 
Table 12. List of all recorded adverse events 
 Pyronaridine-artesunate 
n=53 
Artemether-lumefantrine 
n=27 
Total AE 76 40 
 n % n % 
Upper Resp Tract 
Infection 
35 46 22 55 
Pyrexia 8 11 3 7 
Vomiting 2 3 4 10 
Abdominal pain 3 4 5 13 
Diarrhea 1 1 1 2 
Conjuntivitis 4 5 0 0 
Skin infection 4 5 1 2 
Skin eruption 2 3 1 2 
Headache 0 0 2 5 
Varicela 1 1 1 2 
Tinea Capitis 2 3 0 0 
Anorexia 2 3 0 0 
Stomatits aphtosa 2 3 0 0 
Splenomegaly 2 3 0 0 
Anemia 2 3 0 0 
Creatin-kinase increased 1 1 0 0 
AST/ALT increased 1 1 0 0 
Furuncle 1 1 0 0 
WBC increased 1 1 0 0 
Urinary tract infection 1 1 0 0 
Hookworms 1 1 0 0 
Number of cases and rate of all adverse events regardless of relationship to medication 
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4.4.2 Incidence of Drug-related Adverse Events 
Adverse events designated by investigators as related to the study drugs 
occurred in 6/53 (11%) of the patients receiving pyronaridine-artesunate and 
6/27 (22%) of those receiving artemether-lumefantrine. All of them were 
considered as “possibly” or “probable” related to the study drugs. The adverse 
events judged drug-related were gastrointestinal disorders (vomiting (3), 
abdominal pain (3) and diarrhoea (2)), anemia (1) headache (2), and blood 
creatin- phosphokinase increased (1). All adverse events were considered of 
mild or moderate intensity and resolved before Day 28 without sequelae. 
Neither serious nor AE leading to study drug discontinuation nor withdrawal 
were related to the study medications. The incidence of study drug related 
adverse events for each treatment group is listed below in Table 13. 
 
Table 13. Drug-related adverse events 
 Pyronaridine-artesunate 
n=53 
Artemether-lumefantrine 
n=27 
 n % n % 
Any drug related AE 6 11 6 22 
Vomiting 2 4 1 4 
Abdominal pain 1 2 2 8 
Diarrhea 1 2 1 4 
Blood creatin-
phosphokinase 
increased  
1 2 0 0 
Headache 0 0 2 8 
Anemia 1 2 0 0 
Incidence of adverse events considered drug-related by investigators. 
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4.4.3 Clinically Significant Abnormal Laboratory Parameter 
Haematological and biochemical parameters were assessed for each patient in 
order to evaluate inclusion and exclusion criteria and to have reference values 
for evaluation of safety during the course of the study. 
Haematology values at baseline were representative for children with acute 
uncomplicated P. falciparum malaria. Mean haemoglobin values were below 
normal range in both treatment groups, 10 g/dl in the pyronaridine-artesunate 
group and 10.2g/dl in the artemether-lumefantrine group. Furthermore, platelets 
were below normal range at baseline, 179000/µl and 201000/µl in the 
respective groups. 
In both treatment groups, haematology results showed mean changes from 
Day 0 in consistence with effective anti-malarial therapy. In the pyronaridine-
artesunate group, mean haemoglobin concentrations decreased on Day 3 by 
0.5 g/dl and recovered by Day 28, while in the artemether-lumefantrine group 
haemoglobin decreased haemoglobin levels by -0.4 on Day 3 and recovered by 
Day 28. By Day 28, haemoglobin mean values reached significant higher levels 
than at baseline in both treatment groups (11.1 g/dl). Corresponding changes in 
RBC and haematocrit followed the same dynamics in both groups, with mean 
values under normal range at baseline (haematocrit: 30.2 and 30.8; RBC: 4.1 
and 4.1, respectively) recovering by Day 28 and reaching higher values than in 
baseline (haematocrit: 33.7 and 33.7; RBC: 4.5 and 4.56, respectively). 
Mean platelet values reached rapidly levels within normal ranges on Day 3 
234000/µl in pyronaridine-artesunate group and 219000/µl artemether-
lumefantrine group, respectively).  
Mean values of white blood cell counts did not show major changes. However, 
mean values for percentage of eosinophils and lymphocytes rose from Day 3 
until Day 28. Eosinophilia at Day 28 in both groups probably reflects endemic 
chronic helminthic infections of a large proportion of the patients. 
 
 
 
Results 
 
59 
 
Table 14. Haematology parameters 
 
 Treatment Group 
Pyronaridine-artesunate Artemether-lumefantrine 
 D0 D 3 D7 D28 D 0 D 3 D7 D28 
Haemoglobin (g/dl) 
Mean(SD)  
10.0 
 (1.0) 
9.7 
(1.1) 
9.65 
(1.1) 
11.1 
(1.0) 
10.2 
(1.1) 
9.8 
(1,3) 
10.3 
(1.28) 
11.1 
(1) 
Haematocrit (%) 
Mean(SD) 
30.2 
 (3.05) 
29.06 
(3.42) 
29.39 
(3.5) 
33.7 
(2.9) 
30.8 
(3.3) 
31.3 
(3.81) 
31.7 
(3.8) 
33.7 
(2.7) 
RBC (Mio/µl)  
Mean(SD) 
4.1 
 (0.5) 
3.95 
(0.55) 
4.0 
(0.6) 
4.5 
(0.5) 
4.1 
(0.53) 
4.15 
(3,81) 
4.28 
(0.61) 
4.56 
(0.49) 
Platelets (T/µl)  
Mean(SD) 
179 
 (95) 
234 
(96) 
360 
(145) 
277 
(90) 
201 
(73) 
213 
(98) 
361 
(121) 
292 
(81) 
WBC (T/µl)  
Mean(SD) 
7.8 
 (2.6) 
8.3 
(3.48) 
10.1 
(3.8) 
9.5 
(2.5) 
7.7 
(2.5) 
7.9 
(2.6) 
9.6 
(3.52) 
10.1 
(3) 
Neutrophils (%) 
Mean(SD) 
39.1 
(14.4) 
27 
(9.57) 
36.6 
(37.9) 
27.7 
(10.5) 
37.8 
(15.7) 
24.65 
(8.5) 
27.3 
(7.9) 
26 
(8.8) 
Lymphocytes (%) 
Mean(SD) 
39.3 
(12.6) 
48.3 
(9.59) 
45.0 
(10.6) 
47.2 
(10.1) 
37.9 
(13.5) 
50 
(10.1) 
47.9 
(9.3) 
48.9 
(9.7) 
Monocytes (%) 
Mean(SD) 
9 
(2.3) 
12.4 
(4.65) 
12.5 
(3.5) 
11.9 
(9.9) 
13.1 
(4.3) 
11.4 
(3.6) 
10.9 
(4) 
9 
(2.3) 
Eosinophils (%) 
Mean(SD) 
4.5 
(4.8) 
9.5 
(8.13) 
9.6 
(7.2) 
11.2 
(1.25) 
6 
(6.5) 
11.3 
(8.9) 
10.8 
(7.1) 
11.8 
(6) 
Basophils (%) 
Mean(SD) 
1.27 
(0.83) 
1.3 
(0.7) 
1,4 
(0.7) 
1.25 
(0.7) 
1.12 
(0.76) 
1.25 
(0.6) 
1.14 
(0.35) 
1.11 
(0.32) 
Summary of haematology values showed by mean (standard deviation) at baseline, 
Day 3, Day 7 and Day  28 after treatment in the ITT population. 
Clinical chemistry values were measured at baseline, Day 3, Day 7 and 
additionally Day 28 if needed. Clinical biochemistry results showed similar mean 
changes from baseline values in the two treatment groups. Baseline mean 
values of albumin, total bilirubin, ALT, urea, creatinine, sodium and potassium 
were as per-protocol criteria, within normal ranges. Moreover, creatinine-kinase, 
alkaline-phosphatase and glucose were also within normal ranges. Mean values 
of AST were slightly over normal range at baseline and normalized from Day 3 
onwards. Laboratory values were classified with regards to their clinical 
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significance. One patient in the pyronaridine-artesunate group showed a peak 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >3 times 
the upper limit of normal (136 IU/l and 126 IU/l respectively) on Day 3. However, 
total bilirubin was below 2 times the limit of normal (6.1 μmol/l) and values at 
baseline were already over normal range. From Day 7 and onwards values 
were within normal range. The episode was considered by investigators as 
clinically significant and classified as an Adverse Event of moderate intensity. 
However, the episode was considered as non-related to study medication. At 
the end of follow up no other abnormal laboratory value was classified as 
clinically significant. 
Table 15. Biochemistry  
 Treatment Group 
Pyronaridine-artesunate Artemether-lumefantrine 
 D0 D 3 D7 D 0 D 3 D7 
Total Bilirubin µmol/L 
Mean(SD)  
14.3 
(9.7) 
5.6 
(2.5) 
7.0 
(2.6) 
12.5 
(12.4) 
5.3 
(2.9) 
6.0 
(2.9) 
Albumin g/dl 
Mean(SD) 
3.7 
(0.4) 
3.6 
(0.3) 
3.8 
(0.3) 
3.7 
(0.5) 
3.6 
(0.5) 
3.9 
(0.3) 
ALT  IU/l 
Mean(SD) 
19.2 
(13.7) 
21.1 
(25.5) 
17.4 
(9.6) 
19.8 
(14.3) 
16.9 
(8.6) 
16.4 
(6.3) 
AST  IU /l 
Mean(SD) 
38.2 
(26.6) 
32.5 
(17.8) 
30.0 
(10.7) 
37.2 
(18.8) 
33.3 
(12.6) 
30.4 
(6.5) 
Creatinine kinase IU/l 
Mean(SD) 
85.9 
(31.3) 
72.0 
(69.7) 
98.3 
(81.4) 
77.0 
(39.9) 
55.8 
(29.9) 
73.0 
(39.7) 
Alk. Phosphatase IU/l 
Mean(SD) 
193.4 
(57.8) 
172.6 
(59.9) 
171.5 
(55.3) 
204.9 
(56.6) 
189.0 
(53.1) 
190.3 
(49.8) 
Urea mmol/l 
Mean(SD) 
7.8 
(8.9) 
7.6 
(7.6) 
7.6 
(9.2) 
7.2 
(7.4) 
7.4 
(7.5) 
7.6 
(8.0) 
Creatinine µmol/l 
Mean(SD) 
34.2 
(12.3) 
34.5 
(10.9) 
35.6 
(18.3) 
36.3 
(8.4) 
35.9 
(8.4) 
35.2 
(9.9) 
Sodium mmol/l 
Mean(SD) 
134.8 
(19.8) 
139.1 
(2.6) 
136.9 
(22.3) 
138.2 
(4.0) 
139.4 
(3.3) 
140.4 
(2.5) 
Potassium mmol/l 
Mean(SD) 
3.9 
(0.4) 
4.0 
(0.5) 
5.1 
(0.5) 
3.9 
(0.4) 
4.1 
(0.5) 
4.4 
(0.5) 
Glucose mmol/l 
Mean(SD) 
21.3 
(33.8) 
22.9 
(34.0) 
23.9 
(34.5) 
26.5 
(38.4) 
23.0 
(33.2) 
16.9 
(30.7) 
Summary of biochemistry values. Mean (standard deviation) at baseline, Day 3 and 
Day 7 after treatment in the safety population. 
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4.4.4 Vital signs, Physical Examination and ECG 
Abnormalities  
Vital signs (blood pressure and pulse rate) were evaluated during the course of 
the study. Values were within the normal ranges for children and infants. As 
expected, mean pulse rate decreased in parallel to fever clearance from 
baseline in both treatment groups (117 bpm in the pyronaridine-artesunate 
group and 114 bpm in the artemether-lumefantrine group), reflecting the 
recovery from malaria episode due to effective anti-malarial therapy. None of 
the patients had a clinically significant ECG finding at baseline or during follow 
up. None of the patients had a significant medical history at inclusion. 
 
Table 16. Vital signs 
 Pyronaridine-artesunate 
n=53 
Artemether-lumefantrine 
n=27 
Mean systolic/diastolic 
blood pressure 
(mmHg) 
Pulse rate 
(bpm) 
Mean systolic/diastolic 
blood pressure 
(mmHg) 
Pulse rate  
(bpm) 
Baseline 94/57 117 92/54 114 
Day 1 92/56 101 91/55 103 
Day 2 89/54 100 92/57 101 
Day 3 92/56 97 91/55 96 
Day 7 89/54 95 89/53 98 
Day 14 91/56 97 94/57 98 
Day 21 92/58 95 92/57 103 
Day 28 94/56 98 90/55 98 
Day 35 92/57 95 90/53 97 
Day42 89/54 95 91/53 95 
Mean values of blood pressure and pulse rate in both treatment groups. Pulse rates 
decreased from baseline onwards probably due to fever clearance. 
 
Discussion 
 
62 
5 Discussion 
_______________________________________________________________ 
During the past years, substantial progress has been made in the fight against 
malaria. In spite of this improvement, malaria remains an extraordinary cause of 
morbidity and mortality worldwide. In the present days, malaria is considered 
endemic in 97 countries and territories around the world. Estimates have shown 
that in 2013 malaria was the underlying cause of death for 584.000 individuals,  
yet children younger than 5 years in Africa accounted for 78% of all deaths [1]. 
Malaria is a curable disease provided prompt diagnosis and adequate 
treatment. It is well known that early diagnosis and rapid and effective treatment 
of malaria disease shortens its duration and prevents the development of 
complications and the vast majority of deaths from malaria. Great improvement 
has been made in the development of effective antimalarial medicines since the 
emergence of resistance to former drugs. At present, the World Health 
Organization recommends treatment of P. falciparum malaria with combination 
therapies, preferably those containing an artemisinin derivative in all countries 
experiencing resistance to monotherapies, such as chloroquine, sulfadoxine-
pyrimethamine and amodiaquine. Artemisinin-based combination therapy has 
been demonstrated as a critical tool for the effective treatment and control of P. 
falciparum malaria. Development of efficacious ACT should take into account 
characteristics such as high schizontocidal and gametocyticidal activity, 
widespread accessibility and good tolerability. Moreover, short regimens, 
affordable price and simple administration are critical aspects for paediatric 
populations. However, there is a lack of adequate paediatric drug formulations 
for most current antimalarial treatment combinations. Evaluation of safety, 
tolerability, efficacy and effectiveness of artemisinin-based combination therapy 
in vulnerable populations living in high malaria transmission areas is one of the 
high priority issues for operational research. The relatively limited experience 
with implementation, registration, marketing, reliable supply and drug quality as 
well as costs and affordability of artemisinin based combination therapy result in 
a major challenge regarding the adequate treatment of malaria in African 
Discussion 
 
63 
regions. Moreover, the potential problems with adherence to co-administered 
non-fixed drug combinations need to be underlined [94]. 
This trial aimed to contribute to the knowledge on the use of pyronaridine-
artesunate combination therapy in African children. The study comprised of 80 
Gabonese children and infants <12 years old suffering from acute 
monoinfection of P. falciparum malaria. As young children have often a less 
favorable response to antimalarial drugs than older children and adults even in 
areas of low malaria transmission, the World Health Organization’s 
recommendations are to  emphasize treatment evaluations in young children 
[88]. Our trial population matched therefore with these recommendations 
targeting infants and children below 5 years of age.  
Among all included patients, only one patient was lost to follow-up due to 
consent withdrawal. Follow-up rate was then 99 % over the whole study period 
in the clinical trial. Two patients had reappearance of parasitaemia at Day 28 
and three at Day 42. The study could be therefore analyzed for efficacy and 
safety in 79/80 subjects. As expected in a randomized trial, the distribution of 
background characteristics was comparable between the two groups. Baseline 
clinical and laboratory characteristics as well as vital signs were found to be 
representative of children suffering from acute falciparum malaria in an endemic 
location (i.e. high frequency of heart rate, common hepato-splenomegaly 
anemia, and thrombocytopenia). No significant differences regarding clinical 
and laboratory findings were found between the two groups. 
Patients in the pyronaridine-artesunate group received per dose 7.0: 2.3 mg/kg 
to 13.3: 4.4 mg/kg of pyronaridine tetraphosphate and artesunate sachet-
contained and diluted in non-carbonated liquid up to 150 ml. Patients in the 
artemether-lumefantrine group received per dose 1.6: 9.6 mg/kg to 4.0: 24 
mg/kg of artemether and lumefantrine respectively from crushed tablets and 
diluted in up to 150 mL of non-carbonated liquid. In the pyronaridine-artesunate 
group administration was once every 24 hours for three days. 
The definition for the primary efficacy endpoint was Day 28 PCR-corrected 
ACPR higher than 90%. The Per-Protocol population analysis showed that 
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treatment with pyronaridine-artesunate granules of acute uncomplicated P. 
falciparum malaria in children had a Day 28 PCR corrected ACPR of 100% 
(95% CI 93.2 to 100). Introduction of a new antimalarial requires an efficacy of 
>95% [13]. This trial was statistically powered as part of the entire multicentre 
study (n=600) to demonstrate whether a cure rate higher than 90% could be 
achieved. This was based on the assumption that cure rates would achieve 
95% of efficacy, based on previous studies [76] and because of practical 
reasons in setting a reasonable sample size. Results in our study site were 
highly reassuring by reaching the primary efficacy endpoint and when 
considering the characteristics of the site and trial population: age of the target 
population and high transmission area hyperendemic for P. falciparum malaria 
[79]. Moreover, these results are consistent with the high rates of efficacy 
reported in previous Phase III efficacy trials conducted in children and adults 
with uncomplicated acute P. falciparum malaria and treated with pyronaridine-
artesunate [74, 75]. In 2012, Rueangweerayut et al showed that pyronaridine–
artesunate was non-inferior to mefloquine plus artesunate against P. falciparum 
malaria for the primary outcome: Day 28 adequate clinical and parasitological 
response in the Per-Protocol population, PCR-corrected for reinfection. Efficacy 
in the group treated with pyronaridine– artesunate tablets was 99.2%. 
Moreover, Tschefu et al showed in 2010 that PCR-corrected ACPR cure rate at 
Day 28 of patients with uncomplicated P falciparum malaria was 99·5% (780 
patients; 95% CI 98·7–99·9) in the pyronaridine-artesunate group , in a 
multicentre clinical trial in Africa comparing the safety and efficacy of 
pyronaridine-artesunate with that of artemether-lumefantrine.  
The primary efficacy outcome in this clinical trial was not assessed in the 
youngest age group as no infants under 1 year old were included. Children 
aged 1–5 years who met the primary endpoint and outcomes were similar to the 
older children. Thus, further data to assess to efficacy and safety in very young 
children (<1 year old) are still needed. More extensive clinical use of 
pyronaridine-artesunate in older children and adults should be evaluated to 
demonstrate safety before further studies are conducted in very young children. 
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Regarding the main secondary objective, this study showed that the efficacy of 
pyronaridine-artesunate is non-inferior to that of artemether-lumefantrine for 
treating acute uncomplicated P falciparum malaria in children, measured by 
PCR-corrected ACPR rate at Day 28. This is consistent with previous studies 
[75]. Both treatments were highly efficacious with cure rates of more than 95% 
and no early clinical failures. The efficacy of artemether-lumefantrine was 
consistent with recent reports from other studies in the African and southeast 
Asian countries [95-98]. Additionally, the Day 14 PCR corrected ACPR, as a 
secondary efficacy objective, was equally high in the per protocol population of 
both treatment groups (100%). 
Similarly to the results of the multi-centric study, PCR-corrected rates at Day 42 
were non-significantly different in the pyronaridine-artesunate group than in the 
artemether-lumefantrine group [76]. This is in contrast with previous Phase III 
clinical trials with pyronaridine-artesunate (tablet formulation) where crude 
ACPR rates at Day 28 and PCR-corrected and crude ACPR rates at Day 42 
were higher in the pyronaridine-artesunate group than in the artemether-
lumefantrine group [75]. Moreover, shown in the previous Phase III study, the 
prophylactic effect at Day 42 of pyronaridine-artesunate tablet formulation was 
significantly greater when compared to artemether-lumefantrine (p-
value=0.007). This could be attributed to differences in the transmission rates 
within both studies, or because in the previous study more than half of the 
patients (57%) were older than 12 years and no children under 5 years was 
included. The greater immunity in older children to P. falciparum infection may 
have led to a more prolonged prophylactic effect.  
As expected, both treatments reduced parasitaemia rapidly. Parasite clearance 
was more rapid in the pyronaridine-artesunate group than in the artemether-
lumefantrine group, with the greatest difference between groups seen before 
Day 2 (p-value=0.036), consistent with previous observations [74, 75]. The 
artemisinin component has been pointed out as mostly responsible for the rapid 
parasite clearance. This has been described in studies of other combinations of 
ACT containing dihydroartemisinin or artesunate when compared with 
artemether [97, 98]. Conversion of artesunate into the active form of 
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dihydroartemisinin is faster and more complete than that of artemether. There is 
evidence to suggest that the relative oral antimalarial bioavailability of 
artemether compared with artesunate is lower on the first day of treatment 
(58%, 95% CI 40–76) than on the second day (72%, 44–118; p=0.018) [99]. 
Food intake might also have an effect; artesunate is water soluble, whereas 
artemether is lipid soluble and its absorption is increased when taken with food. 
As the effect of fat for optimizing the absorption of artemether-lumefantrine is 
well-known, this study followed the local recommendations with regards to food 
or milk at the time of drug administration. Though the different local 
recommendations might potentially introduce some variability, results showed 
that the efficacy of artemether-lumefantrine was high across all sites included in 
the trial. Moreover, patients with malaria are often sick on the first day of 
treatment and might be unable to eat, potentially reducing absorption of 
artemether. However, even with the six-dose artemether-lumefantrine regimen, 
doses of artemether might not be completely effective in some patients. In this 
study, the mean artemether dose received was 1.7 mg/kg, ranging from 0.9 
mg/kg to 2.4 mg/kg; artesunate doses ranged from 2.3 mg/kg to 4.7 mg/kg. 
Pyronaridine-artesunate can be given regardless of food intake, as there is no 
known significant food effect associated with the drug. 
Fever clearance rate was clinically satisfactory in both treatment groups and did 
not differ between groups. Median fever clearance time was not significantly 
different with pyronaridine-artesunate (11.5 h; 95% CI 8-16h) versus 
artemether-lumefantrine (9.5 h; 95% CI 8-24; p-value=0.69). However, due to 
concomitant antipyretic treatment in more than half of all patients, no difference 
would be expected. 
None of the patients showed parasitaemia on Day 2 higher than on Day 0, nor 
parasitaemia on Day 3 with temperature > 37.5°C, nor parasitaemia on Day 3 
> 25% of count on Day 0. Thus, no patient met the World Health Organization 
criteria for early treatment failure with regards to parasite and fever clearance. 
Similarly, no World Health Organization criteria for late clinical failure (presence 
of parasitaemia on Day 3 with development of severe malaria or presence of 
parasitaemia an temperature > 37.5°C on any day from Day 4 to Day 14) or late 
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parasitological failure (presence of parasitaemia on Day 14 and temperature < 
37.5°C) was met by any patient [8, 100]. 
All patients presenting gametocytaemia at baseline and patients presenting new 
occurrences after inclusion were cleared before Day 28. Complete gametocyte 
clearance was achieved on Day 28 in the pyronaridine-artesunate group on 
Day 14 in the artemether-lumefantrine group. The percentages of patients 
cleared from gametocytes are in line with the good gametocyticidal effect of 
artemisinins leading to reduced infectivity to mosquitoes by gametocytes in 
peripheral blood [101, 102]. The gametocyticidal effect of artemisinins is one of 
their proposed advantages compared to other drugs such as chloroquine or 
sulfadoxine-pyrimethamine known to induce gametocytogenesis [103-105]. 
However, transmission is only reduced but not prevented by artemisinin-based 
treatments [106] and some authors even claim that the gametocyticidal effect of 
antimalarials favor selection of resistant strains and therefore spread of 
resistance [107]. 
Both treatments were found to be well tolerated. Overall tolerability of 
pyronaridine-artesunate was consistent with that found for both components 
given in monotherapy [43, 67, 70, 71], as well as with that found in previous 
clinical trials with fixed oral tablet and granule formulations [74, 108, 109]. The 
most common drug-related complaints recorded in previous studies evaluating 
pyronaridine-artesunate were mild gastrointestinal disturbances such as mild 
abdominal pain, diarrhea, nausea and vomiting [110]. Other complaints usually 
included dizziness, headache, palpitation and pruritus. Regarding the 
comparator drug, artemether-lumefantrine has been widely and consistently 
studied and is registered in accordance with internationally recognized 
guidelines [111-114], The most commonly reported as possibly related adverse 
effects following artemether-lumefantrine therapy have involved the gastro-
intestinal system (abdominal pain, anorexia, nausea, vomiting, diarrhoea) and 
central nervous systems (headache, dizziness). Pruritus and rash have been 
reported by < 2% of patients [115]. One case-control study found irreversible 
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hearing impairment associated with this treatment combination [116]. However, 
subsequent studies could not reproduce these findings [117]. 
The known adverse event profiles for both pyronaridine-artesunate and 
artemether-lumefantrine were similar to those found in the study. The drug-
related adverse events were found to be similar between the two groups though 
the drug-related adverse events incidence was significantly lower in the 
pyronaridine-artesunate group (11% versus 22% respectively). What is more, 
no clinically relevant differences were found according to the age group analysis 
of adverse events. Nevertheless, when reviewing the safety data of the whole 
multicentre study, distribution and incidence of adverse events were found to be 
similar in both treatment groups [76]. One patient treated with pyronaridine-
artesunate showed a peak of AST and ALT >3xULN, while bilirubin remained 
below 2 times the limit of normal. Values returned within normal ranges from 
Day 7 onwards. The episode was considered by investigators as clinically 
relevant though not study drug related. Regarding the outcome peak of ALT 
>3xULN plus peak of total bilirubin >2xULN, the incidence in the whole 
multicentre study was 0.3% (1/355) in the group receiving pyronaridine-
artesunate and 0.6% (1/180) in the group receiving artemether-lumefantrine 
[76]. Increased transaminases have been observed with pyronaridine-
artesunate tablets (as ALT elevations with increased bilirubin) consistently at a 
similar incidence in two out of four of the preceding Phase I studies and across 
all the previous Phase II/III pyronaridine-artesunate clinical trials. In all patients, 
rises in transaminases peaked around Day 7 and levels were decreasing or 
even had normalized by Day 28. At this time point, no instances of Grade 3 
and/or 4 toxicity were observed. No clinical sequelae related to these changes 
in liver function were noted in any patient. Additionally, an Independent Data 
Monitoring Committee (IDMC) examined the safety liver function data from all of 
the studies. The Committee comprised six members and included three experts 
in hepatotoxicity. The IDMC concluded that pyronaridine-artesunate treatment is 
associated with transient elevated transaminases and that the early onset 
between Day 3 and Day 7 and its rapid resolution were consistent with a direct 
low-level toxicity. Furthermore, as pyronaridine-artesunate is dosed only for 
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three days, the risk of increasing liver injury is small [110]. Further studies 
should be conducted in patients as well as in healthy volunteers in order to 
evaluate the hepatic safety profile of pyronaridine-artesunate when 
administered more than once. 
Abnormal haematology values at baseline were representative for children with 
acute uncomplicated P. falciparum malaria and consisted mostly of low 
haemoglobin, haematocrit and platelet counts rising after effective malarial 
therapy. Nowadays, anaemia in falciparum malaria is explained not just 
because of haemolysis of infected erythrocytes but also because of haemolysis 
of non-infected cells [118], splenic and reticulo-endothelial hyperactivity [119, 
120], suppression of erythropoiesis along with dyserythropoiesis and 
erythrophagocytosis [121-123]. The increase of haemoglobin towards normal 
values is of high importance in malaria endemic areas as chronic anemia 
determines cognitive functioning and development of the children. 
Thrombocytopenia is one of the most common complications P. falciparum 
malaria [124-129]. Despite the dysfunction in the coagulation pathway and the 
prominent thrombocytopenia seen in severe malaria, haemorrhagic 
complications are relatively rare [130]. The speculated mechanisms leading to 
thrombocytopenia are: platelet destruction by antibody-mediation, bone marrow 
alterations, coagulation disturbances, splenomegaly, oxidative stress and the 
waste of platelets as co-factors in triggering severe malaria [131]. All patients 
from both treatment groups showed platelet counts within normal ranges from 
Day 3 onwards and therefor consistent with the recovery from malaria.  
Electrocardiograph results showed no cardiac safety concerns with regarding to 
pyronaridine-artesunate therapy. Prolonged QT interval has been uncommonly 
observed with pyronaridine-artesunate (0.07%) [110]. Prolonged QT has been 
more frequently observed associated with the use of quinoline derivatives such 
as mefloquine (0.7%) and particularly chloroquine (2.7%) [132]. In 1.1% of 
patients receiving pyronaridine-artesunate and 0.8% with artemether-
lumefantrine, bradycardia has been shown as an adverse event [110]. Even so, 
the finding of bradycardia in a cohort of children with acute uncomplicated 
febrile P. falciparum malaria after initiating effective treatment is probably 
Discussion 
 
70 
associated with the resolution of the fever and thus the associated tachycardia. 
To support this presumption, across all treatment groups decreases in mean 
heart rate were noted. This effect has been noticed in many other clinical trials 
of anti-malarial therapy while as patients become afebrile, heart rates return to 
the normal baseline values [99, 133-135]. 
The overall safety and tolerability profile of fixed oral pyronaridine-artesunate 
granulate formulation in acute uncomplicated P. falciparum malaria has been 
confirmed for children and infants less than 12 years old. This is in consistency 
with previous reports for both tablets [74, 75] and granulate formulation [73] of 
the study drug. In a meta-analysis by Kurth et al, it was shown that, rates of 
drug-related gastrointestinal adverse events including  drug-induced vomiting 
were lower with ACT pediatric formulations compared to tablets [136]. In a 
previous trial, drug-related gastrointestinal adverse events in adults and children 
receiving pyronaridine-artesunate tablets were more common (vomiting 3.3%, 
other gastrointestinal adverse events 6.6%) compared to artemether-
lumefantrine (1.9% and 5.2%, respectively) [75]. In this trial, the trend has been 
shown to reverse with pediatric pyronaridine-artesunate granule formulation 
(vomiting 2.0%, other gastrointestinal 2.0%) compared to artemether-
lumefantrine crushed tablets (3.3% and 3.9% respectively). 
Appropriate and registered pediatric drug formulation available for the treatment 
of young children is a major aim of drug-development programs against malaria. 
Young children and pregnant women are particularly vulnerable to malaria and 
clinical research needs to be encouraged in these target populations. 
Pyronaridine-artesunate pediatric granules were efficacious, safe and well 
tolerated in this study in Gabonese children under 12 years of age with 
uncomplicated P. falciparum malaria. Considering these data and in 
consistence with those of the other efficacy trials [74-76], pyronaridine-
artesunate granule co-formulation strikes as being a useful ACT for treating 
uncomplicated P. falciparum malaria in children and infants. 
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6 Conclusion 
______________________________________________________________ 
The study assessed the efficacy and safety of a fixed dose of oral pyronaridine-
artesunate granule formulation (60:20) (paediatric Pyramax®) compared to 
artesunate-lumefantrine (Coartem®) crushed tablets in infants and children with 
acute uncomplicated P. falciparum malaria. The study was part of a multicenter, 
comparative, randomized, open-labeled, parallel group study on the efficacy, 
safety and pharmacokinetics of the investigational drug conducted in a total of 
534 male and female infants and children (between ≥ 5 kg and < 25 kg body 
weight) suffering from acute symptomatic uncomplicated P. falciparum malaria 
recruited from study sites located in Africa and the Philippines. 
A total of 80 subjects with similar demographic and clinical characteristics at 
baseline were enrolled in the study. Fifty-three patients received pyronaridine-
artesunate granule formulation (60:20 mg) daily for 3 days and 27 received 
artemether-lumefantrine crushed tablets as drug comparator. The primary 
outcome was achieved as the cure rate at Day 28 in the pyronaridine-
artesunate group (PCR-corrected ACPR in the efficacy-evaluable population) 
was of 100%. Moreover, non-inferiority of the investigational drug compared to 
artemether-lumefantrine was demonstrated on Day 28 and on Day 42 in the 
efficacy-evaluable population. Furthermore, parasite clearance was significantly 
shorter with pyronaridine-artesunate. Overall adverse events incidence and 
severity were similar between groups. Neither serious nor adverse events 
leading to study neither drug discontinuation nor withdrawal occurred in the 
course of the study. Adverse events considered by investigators as drug related 
occurred in 11% of the patients receiving pyronaridine-artesunate and were 
mostly mild gastrointestinal disorders. Pyronaridine-artesunate pediatric 
granules were efficacious, safe and well tolerated in this study in children under 
12 years of age with uncomplicated P. falciparum malaria. Pyronaridine-
artesunate granule co-formulation appears to be a valuable ACT for use in 
children and infants with uncomplicated P. falciparum. 
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7 Definitions 
_______________________________________________________________ 
Adequate Clinical and Parasitological Response (ACPR): 
ACPR is defined as patients with clearance of asexual parasitaemia without 
recrudescence within 28 days of initiation of study treatment and not meeting 
other criteria of early treatment failure, late clinical failure and late 
parasitological failure. 
Parasite clearance: 
At least two consecutive negative smears for asexual parasites obtained within 
an interval of 8 to 24 hours post-dosing. 
Fever clearance: 
At least two consecutive normal body temperature measurements obtained 
within an interval of 8 to 24 hours post-dosing. 
New Infection: 
New infection is defined as the appearance of asexual parasites after clearance 
of initial infection with a genotype different from those parasites present at 
baseline. New infection must be confirmed by microscopy (positive blood 
smear) and PCR analyses. Confirmed new infection will not be regarded as 
treatment failure or recrudescence. 
Recrudescence: 
Recrudescence is defined as the appearance of asexual parasites after 
clearance of initial infection with a genotype identical to that of parasites present 
at baseline. 
Recrudescence must be confirmed by microscopy (positive blood smear) and 
PCR analyses. Confirmed recrudescence is regarded as treatment failure. 
Treatment failure: 
Treatment failure is classified as: early treatment failure, late clinical failure and 
late parasitological failure and is based on WHO Guidelines 2005.
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